Inpatient Rehabilitation, Diabetes, and the Risk of Clostridium Difficile Infection by Flint, Kerry A
Walden University
ScholarWorks
Walden Dissertations and Doctoral Studies Walden Dissertations and Doctoral StudiesCollection
2018




Follow this and additional works at: https://scholarworks.waldenu.edu/dissertations
Part of the Public Health Education and Promotion Commons
This Dissertation is brought to you for free and open access by the Walden Dissertations and Doctoral Studies Collection at ScholarWorks. It has been

















This is to certify that the doctoral dissertation by 
 
 
Kerry A. Flint 
 
 
has been found to be complete and satisfactory in all respects,  
and that any and all revisions required by  




Dr. Maria Rangel, Committee Chairperson, Public Health Faculty 
Dr. Anita Manns, Committee Member, Public Health Faculty 






Chief Academic Officer 











Inpatient Rehabilitation, Diabetes, and the Risk of Clostridium Difficile Infection 
by 
Kerry A. Flint 
 
MSN, University of New Mexico, 2009 
BSN, University of Phoenix, 2005 
 
 
Dissertation Submitted in Partial Fulfillment 
of the Requirements for the Degree of 









Clostridium difficile is a frequent cause of healthcare-associated infections (HAI) and is 
associated with increased risk of morbidity and mortality.  Studies suggest environmental 
and host characteristics increase patient’s susceptibility to C. difficile infection (CDI).  
However, few studies have examined the risk of CDI among those with diabetes or 
patients in the acute rehabilitation (AR) setting.  A case-control study, using secondary 
data (n = 473), evaluated the relationship between CDI and diabetes and identified 
modifiable environmental exposures.  An ecosocial framework was used to examine the 
relationship between these two complex diseases among hospitalized patients in an AR 
setting.  Results of the multiple logistic regression showed that patients with diabetes 
experienced 2.5 times the risk for CDI (p = 0.03) compared to non-diabetic patients.  
Multiple logistic regression was also used to assess for modifiable exposures among AR 
patients with diabetes only.  Findings from this sub-analysis found the significant 
exposures in this population were antibiotics (OR = 3.9; p = 0.01) and insulin use (OR = 
2.6; p = 0.015), suggesting an effect on the intestinal microbiome.  Understanding the 
relationship between CDI and diabetes among the AR population promotes positive 
social change through the reduction of CDI associated morbidity and mortality among 
diabetic patients.  Findings from this study support antibiotic stewardship efforts across 
the spectrum of healthcare delivery and the development of new strategies to decrease the 
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Chapter 1: Introduction to the Study 
Introduction 
A key public health issue is healthcare-associated infections (HAI) and the 
prevention of these infections as a measure of healthcare quality.  This research study 
proposes to investigate the relationship between diabetes and Clostridium difficile 
infection (CDI) in a healthcare setting.  C. difficile is a spore forming bacteria found in 
the environment that affects a range of outcomes in those infected.  Outcomes range from 
mild or moderate diarrhea, to severe life-threatening inflammation of the colon, and death 
(Cohen et al., 2010).  Increasing prevalence of CDI in the United States in recent years 
has resulted in a multiple level approach to prevention (The White House, 2015).  This 
study will evaluate the relationship between diabetes and CDI to support efforts to reduce 
the incidence of CDI among hospitalized patients.  People with diabetes are a population 
group with frequent healthcare exposure across the continuum of healthcare delivery 
(Booth & Hux, 2003).  Understanding the relationship between different population 
groups can promote positive social change by identifying and targeting infection 
prevention measures in a population group with high healthcare utilization and exposure.  
Prevention efforts, in turn can improve healthcare outcomes and reduce the costs of 
healthcare delivery.  Information gained from this research has the potential to inform 
and support healthcare professionals and public health policy makers’ efforts to 
implement clinically relevant and effective decisions related to CDI prevention. 
This first chapter presents background information regarding the burden of 
diabetes and CDI, describes the purpose of the study, the research questions and 
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hypotheses this study will address.  The theoretical framework, methodology, definitions, 
assumptions, scope, limitations, and significance of the study are also described in this 
chapter. 
Background 
C. difficile is a leading cause of healthcare-associated infections in the United 
States, associated with increased morbidity and mortality among infected patients (Magill 
et al., 2015; Lessa et al., 2015).  The economic burden is also significant, with estimated 
costs in the billions of dollars annually (Desai et al., 2016).  The Centers for Disease 
Control and Prevention (CDC) has identified CDI as an immediate public health threat 
requiring urgent and aggressive prevention and control measures (Centers for Disease 
Control and Prevention [CDC], 2013).  Efforts to understand the burden of CDI in 
healthcare settings has resulted in national surveillance and reporting of CDI incidence.  
Exposure to antimicrobial agents has been strongly associated with the development of 
CDI, in part due to alterations in host intestinal microbiota (Loo et al., 2011; Owens, 
Donskey, Gaynes, Loo, & Muto, 2008).  Other important factors associated with an 
increased risk of CDI include age and underlying disease, for example, diabetes (Kyne, 
Sougioultzis, McFarland, & Kelly, 2002; Wenisch et al., 2012).  
Diabetes disease presents a significant health burden, affecting a sizable 
proportion of the U. S. population (CDC, 2017).  Evidence that those with diabetes could 
be at increased risk for CDI is unclear and often conflicting (Qu & Jiang, 2014).  In some 
studies diabetes was associated with increased risk for CDI (Shakov, Salazar, Kaqunye, 
Buddora, & DeBan, 2011; Wenisch et al., 2013; Zilberberg, Reske, Olsen, Yan, & 
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Dubberke, 2014), while others report finding no significant association (Daneman et al., 
2014; Freedberg, Salmasian, Friedman, & Abrams, 2013; Henrich, Krakower, Bitton, & 
Yokoe, 2009).  Researchers have also reported lower a risk of severe CDI disease (Rao et 
al., 2013) and CDI mortality among patients with diabetes (Stewart & Hollenbeak, 2011), 
In addition, studies examining CDI risk factors have not specifically included diabetes as 
a variable (Loo et al., 2011; Morrison et al., 2011). 
The relationship between diabetes and CDI is plausible (Qu & Jiang, 2014).  It 
has been suggested that the presence of diabetes increases susceptibility to infectious 
agents through alterations in immune function (Bertoni, Saydah & Brancati, 2001; Muller 
et al., 2005; Shah & Hux, 2003).  Such susceptibility to infections may lead to increased 
exposure to antibiotics.  Changes in the gut microbiota following exposure to 
antimicrobials could explain the increased risk for CDI associated with recent antibiotic 
use (Theriot et al., 2014), by providing an opportunity for C. difficile to germinate and 
grow.  There is also evidence demonstrating that C. difficile growth is aided by elevated 
sialic acid levels (Ng et al., 2013).  Sialic acid, a protein bound carbohydrate, is found in 
higher concentrations among diabetics compared to non-diabetics (Varghese, Asha, 
Celine, & Prasanna, 2015).  Differences in the ratios of gut microbiota utilizing sialic 
acid as an energy source exist between those with and without diabetes disease (Larsen et 
al., 2010).  Differences and alterations to the gut microbiota of diabetic patient’s due to 
host-derived sialic acid levels (Jandhyala et al., 2015) and increased exposure to 
antimicrobials would suggest an increased risk for CDI among diabetics not consistently 
supported in the literature (Qu, & Jiang, 2014). 
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Purpose of Study 
The primary purpose of this quantitative case-control study is to assess the 
association between diabetes and CDI while controlling for selected environmental and 
host characteristics.  The independent variable is a diagnosis of diabetes disease, and the 
dependent variable, a laboratory confirmed test for C. difficile.  A second aim of this 
study is to identify modifiable environmental and host characteristics that increase the 
risk of CDI among hospitalized diabetics.  The independent variables of interest are 
antibiotic use, gastric acid suppressants, and body mass index(BMI).  The dependent 
variable is CDI.  Control variables include age, ethnicity/race, gender, admission 
diagnosis, comorbidities, functional status, and diabetes disease severity. 
Research Questions and Hypothesis 
Research Question 1:  Is there any relationship between diabetes and CDI among 
hospitalized patients in the acute rehabilitation (AR) setting? 
Ho1: There is no relationship between diabetes disease and CDI among patients in 
the AR setting.  
H11: There is a significant relationship between diabetes and CDI among patients 
in the AR setting. 
Research Question 2: Are modifiable environmental (antimicrobial and 
medication exposures) and host characteristics (behaviors, BMI, diabetes management) 
associated with CDI among hospitalized diabetics in AR settings? 
Ho2:  There is no relationship between selected modifiable variables and CDI 
among diabetic patients in the AR setting. 
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H12: There is a relationship between modifiable variables and CDI among 
diabetic patients in the AR setting. 
Theoretical Framework 
An ecological theoretical model is used to frame and guide this research study.  
The ecological perspective uses a system- based approach; examining patterns of health 
within the context of dynamic interrelationships between the biological, physical, social, 
cultural, and historical contexts existing at the local and global level, as well as individual 
attitudes and behaviors (McLaren & Hawe, 2005; Satariano, 2006).  Ecological theory is 
grounded in the assumption that demographic and socioeconomic differences influence 
susceptibility and resilience to health risks (Satariano, 2006).  Krieger (2011) further 
developed this theory in the field of epidemiology, considering the multiple pathways 
affecting the distribution of health and disease in populations.  The key construct of 
Krieger’s ecosocial theory is embodiment.  Embodiment describes the biological 
integration of social and ecological context through socially patterned and exposure-
induced pathogenic pathways.  These pathways are mediated by physiology, behavior, 
and gene expression that affect the development of health and disease states (Krieger, 
2012).  Krieger’s (2008) ecosocial theory provides a framework to examine relationships 




Figure 1.  The ecological and ecosocial concepts used as the theoretical framework to 




Both diabetes and CDI are diseases associated with multiple risk factors 
contributing to disease onset.  Ecological and ecosocial theory provides a framework to 
examine the complex connections that frequently exist between disease and health.  
Diabetes, a chronic disease, has multiple pathways contributing to disease onset and 
complications of disease (Hill et al., 2013a).  CDI is also complex, in terms of exposure 
risks associated with health care utilization (Burke & Lamont, 2014).  An ecological 
perspective expands on the agent, host, and environment concepts associated with 
infectious disease epidemiology by acknowledging the broader context in which 
infectious diseases occur and transmit among susceptible hosts (Satariano, 2006; Smith et 
al., 2005).  The ecological perspective also expands the biomedical perspective of 
infectious disease causation and treatment (Armstrong, 2000), often present in healthcare 
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settings.  Identifying effective prevention measures requires an understanding of the 
multiple pathways contributing to disease.  Satariano (2006) suggests the ecological 
approach examines the context in which individual’s function and respond, and provides 
the opportunity for public health intervention when considering health through an 
integrated and multilevel lens.  Hill, Nielsen, and Fox (2013) also suggest the use of an 
ecosocial perspective to frame prevention efforts.  Especially, as this perspective 
considers the environmental factors, social determinants, and the influence of public 
policy on individual and population health and related behaviors (Hill, Nielsen, & Fox, 
2013). 
Nature of the Study 
This study is observational in nature, using a case-control design to examine the 
association between diabetes (independent variable), and CDI (dependent variable) 
among adult patients in the AR setting.  A case-control design allows the investigation of 
associations between exposure and outcome.  In case-control designs, cases, those known 
to have the outcome of interest (dependent variable), are compared to a similar group in 
which the outcome is absent (Szklo & Nieto, 2014).  Comparison data regarding 
exposure histories (independent variables) between the groups are analyzed to identify 
factors associated with an increased risk of developing the disease or outcome of interest 
(Szklo & Nieto, 2014).  The decision to use a case-control design lies in its suitability to 
investigate rare or infrequent outcomes, less than 20% (Aschengrau & Seage, 2008).  
Previously published CDI estimates in the AR, indicate a prevalence of 15% (Mylotte, 
Graham, Kahler, & Goodnough, 2000).  Cases, defined as AR patients with a diagnosis 
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of CDI, and controls, AR patients without a diagnosis of CDI, were drawn from the same 
hospital population during the defined study period.  Covariates of interest include sex, 
race/ethnicity, BMI, and admission diagnosis.  Other covariates include exposure to 
medications (antibiotics, gastric acid suppressants, insulin, and oral antihyperglycemics) 
environmental exposures (feeding tubes, prior locations), and comorbidity indices which 
include cardiovascular disease, chronic kidney disease, hypertension, liver disease, and 
dementia.  
AR facility administrative data using International Classification of Diseases – 9th 
Revision (ICD-9) diagnostic codes was used to identify cases and controls.  Information 
on independent variables for study participants was extracted from the AR facilities 
medical records.  Analysis methods included descriptive statistics and logistic regression 
modeling. 
Definitions 
Acute Rehabilitation (AR) Hospital: A specialized inpatient setting for improving 
a person’s health, function, mobility and independence following injury or illness, so they 
may successfully return to home, work, and community activities (American Medical 
Rehabilitation Providers Association [AAPM&R], 2016).  Admission to acute medical 
rehabilitation is based on the functional and/or cognitive deficits of the patient, the need 
for medical supervision, the patient’s ability to participate in therapies, and realistic 
outcome goals (American Academy of Physical Medicine & Rehabilitation, 2012).  
Participation requirements include the ability to participate in at least three hours of 
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therapy a day or 15 hours per week (Centers for Medicare & Medicaid Services [CMS], 
2012.). 
Binary Toxin: A toxin consisting of two separate components.  Select strains of C. 
difficile bacteria can produce binary toxins composed of an enzymatic activator and a 
receptor-mediated binding component (Barth, Aktories, Popoff, & Stiles, 2004; Gerding, 
Johnson, Rupnik, & Aktories, 2014).   
Chronic Kidney Disease (CKD): describes the loss of kidney function, which may 
result in end-stage renal disease requiring dialysis therapy.  The assessment of the 
presence of chronic kidney disease in study participants was based on documentation in 
the medical record at time of admission.  
Clostridium difficile: A spore-forming, gram-positive anaerobic bacillus that 
produces two exotoxins, toxin A and toxin B, causing symptomatic infection (Carrico, 
2013; Goudarzi, Seyedjavadi, Goudarzi, Aghdam, & Nazeri, 2014). 
Clostridium difficile infection (CDI): A disease caused by the toxins produced by 
the organism Clostridium difficile (Carrico, 2013).  
Comorbidity: The presence of additional diseases in relation to an index disease in 
a single individual.  The term is used to measure the overall impact of multiple diseases 
in an individual (Valderas, Starfield, Sibbald, Salisbury & Roland, 2009, p. 3.59). 
Exotoxin: A “protein produced by a bacterium and released into its environment 
causing damage to the host by destroying other cells or disrupting cellular metabolism” 
(Carrico et al., 2013). 
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Healthcare associated infection (HAI): Infections that occur while patients are 
receiving treatment for medical or surgical conditions.   
Microbiota: “ecological community of commensal, symbiotic, and pathogenic 
microorganisms that literally share our body space” (Lederberg & McCray, 2001, para. 
8).  Intestinal microbiota describes the resident microorganisms in the intestine. 
Proton pump inhibitors (PPI):  A class of medications which inhibit gastric acid 
secretion by the inhibition of the H+/K+ ATPase, in the parietal cells of the stomach.  PPI 
are used for the treatment of gastric and duodenal ulcers, gastroesophageal reflux disease, 
and other excessive gastrointestinal acid secretory disorders (Drugs.com). 
Social determinates of health: “the circumstances, in which people are born, grow 
up, live, work and age, and the systems put in place to deal with illness.  These 
circumstances are in turn shaped by a wider set of forces: economics, social policies, and 
politics” (World Health Organization, 2008). 
Assumptions 
The nature of this study assumes both cases and controls are from a dynamic 
population, and that the control group is representative of the base population that 
produced the cases (Aschengrau & Seage, 2008).  Therefore, it is assumed that should a 
member of the control group develop CDI, they would meet the case criteria.  The 
selection of cases and controls impacts the internal validity of the data (Szklo & Nieto, 
2014).  The assumption that both cases and controls are representative of the population 
from which the sample is drawn relates to the external validity of the results (Creswell, 
2009; Szklo & Nieto, 2014).  In this study, cases and control subjects are drawn from a 
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post-acute inpatient population.  Admission to post-acute inpatient medical rehabilitation 
is based on functional deficits, medical needs, and ability to participate in therapies 
(AAPM&R, 2012; CMS, 2016).   It is assumed that patients admitted to this setting meet 
the criteria for inpatient rehabilitation as defined by the Centers for Medicare and 
Medicaid (CMS, 2016).  It is also assumed that documentation of diabetes and other 
health and demographic related information represents accurate reporting of information 
by the patient and healthcare providers.  Another assumption of this study is that 
laboratory tests positive for C. difficile toxin reflect an infective process, leading to the 
clinical decision to test for a causative agent based on clinical guidelines (Cohen et al., 
2010).  A final assumption is that susceptibility to disease encompasses the historical, 
cultural, environmental, and socioeconomic factors and exposures across the life course 
of individuals. 
Scope and Delimitations 
The scope of this study includes adult patients, over 18 years of age, admitted to 
an acute medical rehabilitation hospital in New Mexico between January 1, 2009, and 
September 30, 2015.  Case finding used ICD-9 discharge diagnosis code 008.45 and a 
positive laboratory confirmed test for C. difficile toxin.  Positive test results included the 
detection of toxins A or B, detection of C. difficile cytotoxin by PCR, or positive culture 
for C. difficile.  Controls included patients over 18 years of age admitted to the same 
facility without a diagnosis of CDI during their hospitalization.  Diabetic patients were 
persons with a preexisting diagnosis of diabetes at the time of admission.  Due to the 
inability to accurately differentiate between T1D and T2D, all diabetic patients were 
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included.  Exclusions included patients 18 years of age or younger, and those admitted to 
the facility with a diagnosis of CDI and receiving treatment on admission.    
Limitations 
Design and methodology limitations include the observational nature of the study, 
which allows conclusions of association between variables but prevents establishing 
cause and effect.  Use of medical records to collect information on variables equates a 
secondary data source.  Secondary data sources are a recognized limitation as data was 
originally collected as part of the routine care of patients and not the purposes of this 
study.  This limitation can affect the quality of the data due to missing or incomplete data, 
inconsistencies in documentation between healthcare professionals, errors in 
transcription, and misclassification of information during abstraction and coding.  In 
addition, self-reported information regarding race and ethnicity, and behaviors' such as 
smoking are subject to recall bias.  Measures to address this limitation include the 
exclusion of cases with missing variables from the analysis.  Selection bias is a concern 
in case-control designed studies when differences exist in the selection of cases and 
controls.  This bias can occur when cases and controls are selected using different source 
populations and different selection criteria.  The use of a convenience, non-probability 
sampling method also increases the potential for selection bias.  Measures to overcome 
this limitation include selecting both cases and controls from the same hospital 
population, during the same time-period.  Due to the infrequency of cases randomized 
sampling techniques were not utilized. 
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Generalizability to all healthcare facilities is another limitation.  The study 
population is limited to those admitted to an inpatient rehabilitation setting and findings 
may not transfer to other healthcare or community settings.  Population differences 
resulting from a single state in the Southwest region of the United States may also limit 
generalization of findings to other geographical regions. 
Significance 
This study, assessing the association between diabetes and risk for CDI has the 
potential to effect positive social change in several ways.  The effects of positive social 
change could be measured through the reduction of CDI associated morbidity and 
mortality among diabetic patients, and through reductions in the economic burden 
associated with this infection.  Results of this research could also contribute to the current 
body of knowledge regarding risk factors associated with CDI in hospitalized patients by 
identifying modifiable risk factors in this population.  Determining the effect of 
environmental and patient level characteristics is important to prevent the onset of 
primary or recurrent infection.  In addition, investigating the relationship between 
diabetes and CDI within an ecosocial context could advance the theory that diabetics 
develop unique intestinal microbiota and disruptions to this microbiota that contribute to 
an increased risk for CDI.  
 CDI can negatively affect quality of life related to physical and social 
functioning, and fear of recurrent disease (Guillemin et al., 2014; Weaver et al., 2017).  
Patients with CDI may require readmission to the acute care setting.  Readmission to 
acute care not only affects the patient’s rehabilitation progress but also can have financial 
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consequences for AR facilities (Ottenbacher et al., 2015).  Identifying modifiable risk 
factors among diabetic patients has implications for patient education and patient 
participation in activities to reduce their risk for CDI.  Clinical implications from this 
research include identification and mitigation of risk among AR patients related to 
differences in disease characteristics, and decisions regarding CDI prevention and 
treatment options.  Identification of risk factors in the AR population also has the 
potential to support future research including clinical trials for medical interventions such 
as fecal transplants, as well as antibiotic and vaccine research. 
Summary 
CDI presents a significant risk to hospitalized patients and the public’s health as a 
leading cause of HAI.  The emergence more virulent and resistant bacterial strains of C. 
difficile highlights the need for concern among healthcare providers and consumers 
(Carrico, 2013).  Studies examining the prevalence of CDI in the United States have 
focused on acute care settings (Magill et al., 2014) and risk factors associated with such 
settings, limiting assessment of disease risks in post-acute settings (DePestel & Aronoff, 
2013).  In addition to the burden of CDI, the prevalence of diabetes in U.S. is estimated at 
14% of the population (Menke, Casagrande, Geiss, & Cowie, 2015), with more than one 
million new cases diagnosed each year (CDC, 2015, 2017).  Patients with diabetes 
experience high exposure to healthcare and subsequent risk for HAI (ADA, 2014).  
Diabetes has been identified as a potential risk factor in the development and 
severity of CDI (Wenisch et al., 2012).  However, associations between the two variables 
are not clearly established in the literature, and few studies have specifically investigated 
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diabetes and risk for CDI (Eliakim-Raz et al.,2015).  Assessing the relationship between 
diabetes and CDI plays an important role in limiting morbidity and mortality in the 
diabetic population, and identifying variables that could reduce exposure and subsequent 
development of CDI 
Chapter 2 will present a review of the published literature related to the 
independent and dependent variables, providing support for the inconclusive findings 
regarding an association between diabetes and CDI.  Chapter 2 will critically review 
studies to support the research problem, the research questions, and the significance of 
the study.  This review of the literature will also present research establishing the 
theoretical framework used to identify selected variables and guide the analysis and the 
interpretation of the study results. 
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Chapter 2: Literature Review 
Introduction 
The purpose of this study is to evaluate the association between diabetes and the 
risk of Clostridium difficile infection (CDI) among hospitalized patients in post-acute 
settings and to identify modifiable environmental and host characteristics.  Diabetes is a 
chronic metabolic condition affecting more than 12% of the U. S. population (CDC, 
2015, 2017).  Persons with diabetes experience increased morbidity and mortality from 
disease-related complications (ADA 2014, CDC, 2017), resulting in a greater need for 
healthcare services.  Frequent exposure to healthcare services and the healthcare 
environment may place patients at increased risk for HAI (ADA, 2014).  The elevated 
risk for HAI is also supported by Gan (2013) who suggests host characteristics associated 
with diabetes can increase susceptibility to infection. 
Clostridium difficile has become a leading cause of HAI in the United States 
(Magill et al., 2014).  CDI is also associated with increased morbidity and mortality, 
especially as resistant and increasingly virulent strains of C. difficile, such as genotype 
027/BI/NAP1 emerge (He et al., 2013; Hensgens, Goorhuis, Dekkers, Van Benthem, & 
Kuijper, 2013; Lessa et al., 2015).  The increasing burden of CDI in healthcare settings 
also has economic implications related to both in direct costs and indirect societal costs.  
Total direct and indirect costs associated with healthcare-acquired CDI are estimated to 
cost the U. S. 4.7 billion dollars annually (Desai et al., 2016).  A marked increase over 
previously reported estimates of almost 800 million dollars using 2008 data (McGlone et 
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al., 2012).  Review of the literature regarding CDI suggests environmental, and host 
characteristics increase susceptibility to CDI across a variety of healthcare settings. 
The purpose of this review is to present an overview of the literature significant to 
this research topic.  In addition, this literature review will show how the interplay 
between environmental and host characteristics supports the plausibility of a relationship 
between diabetes and CDI.  An expansive body of literature exists across disciplines and 
populations related to diabetes and C. difficile.  However, research examining the 
relationship between diabetes and CDI is limited, leaving a void in our understanding of 
the risk and impact of CDI in diabetic patients in healthcare settings. 
The first section of this chapter begins with a description of the methods and key 
terms used to search the literature relevant to this research issue.  This is followed by a 
description of the theoretical foundation and the relevance in addressing this research 
issue, a comprehensive review of the literature related to the key variables, and 
conclusions based on the information presented. 
Literature Search Strategy 
A search of the literature was conducted to evaluate the current body of 
knowledge regarding the relationship between diabetes and CDI.  The following search 
engines and databases, accessed through Walden University Library services were 
utilized:  EBSCOhost, CINAHL & Medline, ProQuest, and Science Direct.  Internet 
searches using the search engine Google Scholar were also conducted.  The Walden 
University Library location service requested difficult to obtain peer-reviewed articles.  
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Bibliographies of published studies and review articles were also used to identify relevant 
studies.  
Key search words and terms were employed to identify pertinent articles related 
to the research questions.  Keywords were linked by Boolean search terms and included 
the following:  
•    Clostridium difficile, or C. difficile, or CDI, and diabetes, C. difficile and risk 
factors, C. difficile and rehabilitation.  
•    Diabetes and infection, and inflammation 
•    Gut motility, gut microbiota  
•    Ecosocial theory, ecosocial theory and diabetes, ecosocial theory and diabetes, 
diabetes and health disparities 
Scope of Literature Review 
The scope of the literature review included an extensive search of published 
materials in the past five years, extending into the past 20 years.  Much research 
examining risk factors for CDI occurred in the late eighties and early nineties.  As 
concerns regarding the prevalence of CDI have grown, there appears a resurgence of 
research building on prior findings, particularly in genomic research.  A variety of 
literature was reviewed and includes various methodologies, ranging from experimental 
in vitro studies, observational studies, meta-analysis, and reviews.  Literature sources 
included published peer-reviewed journal articles, published dissertations, and infectious 
disease and disease prevention texts. 
19 
 
Current Research Issues  
A large body of current literature exists related to C. difficile and diabetes as 
independent topics.  A search of the ProQuest Dissertations and Theses database 
identified several dissertations investigating CDI in both human and animal populations.  
However, limited literature regarding C. difficile in diabetic or AR populations was 
identified.  The overall increase in publications over recent years, suggests unknown 
factors contribute to CDI disease, including identification of high-risk groups, and 
effective prevention measures across healthcare settings. 
Theoretical Foundation 
Ecosocial theory describes an epidemiology theory of disease distribution.  Nancy 
Krieger proposed this theory 1994 to address the limitations of traditional causal 
relationships between specific agents and diseases to explain patterns and process of 
disease (Krieger, 1994; Krieger, 2011).  Ecosocial theory is one of several multilevel 
social-ecological approaches identified in the literature, where health outcomes are 
studied within the broader social and environmental systems in which people operate 
(Susser & Susser, 1996).  Krieger’s Ecosocial theory expands previous works in 
epidemiological theory to include multiple system levels and tempo-spatial factors, such 
as place of residence or community setting, and history to provide greater context when 
describing factors contributing to health status and outcomes (Krieger, 2011). 
Major Theoretical Propositions 
Several core propositions underpin Ecosocial theory.  These propositions have 
application in understanding the relationship between diabetes and CDI.  The premise of 
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Krieger’s (2011) ecosocial theory is that peoples’ states of health, and disease, are shaped 
by the literal embodiment of the lived experience in both social and ecologic contexts.  
Thus, the way in which people live and interact within the world around them is 
determined by current and changing societal arrangements of power, property, 
production, and reproduction of social and biological life.  Krieger defines embodiment 
as the biological manifestation of cumulative exposures to the material and social world 
in which we live, across the life course from utero to death (Krieger, 2005).  Societal 
arrangements and patterns influence the distribution of disease at various levels and along 
different spatiotemporal scales in response to capacity and resources.  For example, 
multiple socioeconomic and environmental exposures during one’s life have been 
identified as contributing to the biological embodiment of both diabetes and CDI (Eze et 
al., 2014; Kivimäki et al., 2015; Stringhini, Zaninotto, Kumari, Kivimäki, & Batty, 2016).  
Krieger (2011) also suggests that understanding the distribution of disease exclusively 
from a disease process perspective fails to adequately explain why and how disease 
patterns change over time and space (p. 215).  Rather, ecosocial theory allows one to 
consider how exposure, susceptibility, and resilience to social and biological phenomena 
over time create causal pathways leading to a state of embodiment. 
Analysis of the Literature 
Ecosocial theory provides a framework to examine the social and ecological 
factors contributing to health and health outcomes in epidemiologic and social research.  
Previous works incorporating ecosocial theory include position papers examining the role 
of ecosocial theory in public health research and public health policy (Bisung & Elliot, 
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2014) and research studies across a broad range of health issues (Krieger et al., 2013; 
Phillips et al., 2013; Shavers, Klein, & Fagan, 2012; Yamada & Palmer, 2007).  Studies 
using an ecosocial perspective address health outcomes across a variety of population 
groups, with Krieger, frequently noted as the principal author.  The variables most often 
examined within the ecosocial framework are gender, race, ethnicity, and socioeconomic 
disparities in health outcomes across a range of chronic and infectious diseases.  
Ecosocial theory has also provided the theoretical framework in recently published 
doctoral dissertations using qualitative and quantitative designs (Alford, 2014; Eke, 2013; 
Marley, 2013).  Although several social-ecological theories have been proposed in recent 
years (Krieger, 2011; McLaren & Hawe, 2005), the increasing use of ecosocial theory in 
dissertations (Alford, 2014; Eke, 2013; Marley, 2013) likely reflects increased 
recognition of the complexities surrounding health behaviors' and outcomes.  Despite the 
potential of ecosocial theory to frame complex health issues, application of ecosocial 
theory in understanding CDI is limited.  The concepts of multiple pathways of exposure 
that people experience across their life-course could influence their susceptibility or 
resistance to this infection and may help identify disparities in disease distribution 
Ecosocial Theory and Diabetes 
Research into complex public health issues such as diabetes often uses an 
ecological or multifaceted approach (Trickett & Bheeler, 2013).  Krieger (2005) suggests 
an ecosocial approach is well-suited to understanding the multiple factors contributing to 
disease onset and related outcomes through the connection of biological and social 
constructs.  Despite the potential of ecosocial theory in diabetic research, researchers 
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examining diabetes within this framework is limited, with dissertation research 
predominating.  Marley (2013) conducted a qualitative study examining the association 
between the place where people live and the associated cultural, political, and social 
context, and diabetes among White Mountain Apache.  In this study, diabetes represented 
the biological expression of embodiment, through cumulative exposure to environmental, 
social, political, historical, and natural factors.  Crocker (2013) also used ecosocial theory 
to frame a quantitative analysis describing the health characteristics and social 
determinants of Aboriginal peoples living outside tribal reservation with and without 
diabetes in Canada. 
Multiple causal pathways can lead to the onset of disease, and the ecosocial 
concept of embodiment includes social, economic, environmental, political exposures.  
The term social determinates of health describing the conditions in which people live, 
learn, and work is one such pathway.  Diabetes disease is strongly linked to social and 
economic conditions (Clark & Utz, 2012).  Hill et al. (2013) note factors contributing to 
diabetes incidence and effective diabetic management are multi-level and impacted by 
social, environmental, political, and historical context.  They also discuss the 
responsibility of public health agencies in reducing health disparities through data 
collection and research.  These research responsibilities align with the ecosocial concept 
of agency, which refers to the need to monitor, address and explain disparities in health 
outcomes.  Krieger (2011) describes the concept of agency as a responsibility of 
epidemiologic researchers.  Although Hill et al. (2013) did not explicitly discuss 
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ecosocial theory or the concept of embodiment, their article did detail the conceptual 
pathways that can lead to disease.   
Other multilevel theories incorporating social and ecological aspects similar to 
ecosocial theory occur in diabetic population research.  Chang and colleagues (2013) 
examined characteristics associated with diabetes in a Hispanic population living in a 
U.S. border town, using a socio-ecological framework.  Findings from their multivariate 
analysis showed dietary and biological factors most strongly associated with diabetes.  
The authors used a multilevel socio-ecological framework which incorporated the 
complexity and interrelatedness that exists between individual, relationship, community, 
and societal factors.  There are similarities between socio-ecological models and the 
ecosocial theory proposed by Krieger.  Both theories examine the interrelationships 
between exposure and societal and ecosystem levels, but ecosocial theory also considers 
how different temporal and spatial scales influence current and changing patterns of 
health inequalities (Krieger, 2011, p.223). 
Rationale for Theory Selection 
Ecosocial theory provides a dynamic and multilevel theoretical framework for 
research evaluating the association between diabetes and CDI in an AR setting.  This 
framework offers a way to explain how the accumulation and interaction of different 
environmental conditions and experiences of hospitalized patients across the continuum 
of care may impact susceptibility or resilience to disease (Krieger, 2001; Schneiderman, 
Ironson, & Siegel, 2005).  The concept of embodiment and the multifactorial pathways of 
disease causation are applicable to understanding the complexities associated with CDI 
24 
 
and diabetes.  For example, ecosocial theory provides a bridge connecting the physical 
and social environments in which people live and interact and the complex ecological 
structure of the intestinal microbiome.  The intestinal microbiota forms unique 
ecosystems which develop in response to various environmental and biological exposures 
over an individual’s life-course (Rajilić-Stojanović, 2013).  Krieger’s ecosocial theory 
focuses on factors contributing to the distribution of disease not only from a life-course 
perspective but also via multilevel processes and ecosystems.  Such multilevel processes 
and ecosystems can range from the individual micro level to global scale considerations 
(Krieger, 2011).  Using the ecosocial theory of distribution to view the issue of CDI 
among the diabetic population supports examining the issue at the individual, 
organizational, and population level.  It also acknowledges host and environmental 
factors that may contribute to an increased susceptibility or resilience based on previous 
exposures and life course events.  In addition, consideration of the ecosocial pathways 
leading to CDI disease could identify opportunities for disease prevention 
Literature Review Related to Key Variables and Concepts 
Clostridium difficile Infection  
C. difficile is a recognized pathogen in healthcare settings and a leading cause of 
pseudomembranous colitis (Carrico, 2013).  Today, C. difficile is a leading cause of HAI 
(Magill et al., 2014).  Lessa et al. (2015) reported an estimated 66% of CDI cases are 
healthcare related compared to community acquisition.  Similar estimates are also 
reported by Olsen and colleagues (2016) across three national administrative databases.  
The CDC considers C. difficile a high-level and urgent threat to public health.  This basis 
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for this assessment by the CDC comes from the organism’s natural resistance to multiple 
antibiotics and the social and economic costs associated with this infection (CDC, 2013). 
Researchers have consistently identified increased morbidity and mortality related 
to CDI across a variety of patient populations.  Bartlett and colleagues (1978) first 
reported C. difficile as the causative agent in pseudomembranous colitis, refuting 
previous assumptions that it was non-pathogenic (Bartlett, 2008).  Experimental studies 
investigating the action of C. difficile toxins suggest there are several mechanisms by 
which both toxins damage and destroy cells, resulting in increased permeability and 
inflammation of the intestine (Pruitt & Lacey, 2012), and systemic disease (Steele et al., 
2012).  Complications from CDI can result in prolonged hospitalization, the need for 
post-discharge care, and death.  Tabak, Zilberberg, Johannes, Sun, and McDonald (2013) 
estimated CDI attributable risk of death at 4.5%.  However, a recent study by Desai et al. 
(2016) using a broader population base estimated attributable mortality at 10%. 
The ability of C. difficile to cause disease comes from the production of toxins 
(Kelly & LaMont 1998; Kuehne et al., 2010).  Primary exotoxins associated with CDI are 
toxin A (TcdA) and toxin B (TcdB).  A third binary toxin, C. difficile toxin (CDT), has 
been identified in hyper-virulent C. difficile strains (Gerding et al., 2014).  Advances in 
molecular and genomic analyses are enabling researchers to identify the presence of 
specific bacterial strains and toxins (Eckert et al., 2014; Janezic, Marín, Martín & 
Rupink, 2015; Monot et al., 2015).  Experimental studies investigating the action of 
toxins in CDI indicate there are several mechanisms by which both toxins damage and 
destroy cells, resulting in increased permeability and inflammation of the intestine (Pruitt 
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& Lacey, 2012) and systemic disease (Steele et al., 2012).  The presence of toxins not 
only has significance for causing disease but is an essential marker in diagnostic tests.  
Risk factors strongly associated with the onset of CDI are based on disruptions to the 
microbiota of the host and include environmental exposure to antibiotics and gastric acid 
suppressants.  Other environmental factors include exposure to hospital environments.  
Host risk factors identified in the literature include age, gender, race and the presence of 
commodities, including diabetes disease. 
Diabetes 
Diabetes mellitus (DM), describes a chronic condition which results from the 
inadequate production, or the inability to effectively utilize the hormone insulin, causing 
blood glucose levels to increase (International Federation of Diabetes [IFD], 2014).  
There are two main types of diabetes.  The determination as to the type of diabetes 
diagnosed depends on when the presentation of disease occurs and the cause of disease 
onset.  Type 1 diabetes (TD1) typically presents with acute metabolic imbalance 
associated with autoimmune response and non-insulin production in children and young 
adults (Forouhi & Wareham, 2014).  Type 2 diabetes (T2D), the more prevalent of the 
two categories, occurs because of alternations in insulin secretion, and or insulin 
resistance.  T2D is associated with increasing age, obesity, family history of diabetes, 
gestational diabetes, physical inactivity, and race/ethnicity (ADA, 2014; CDC, 2015).  
Dietary risk factors also exist for T2D and which include diets high in red or processed 




Diabetes affects an estimated 23 million adults in the U. S, with T2D accounting 
for 95% of all cases (CDC, 2017).  Disparities in diabetes outcomes occur across a 
variety of population groups, locations, and socioeconomic status.  Fraze, Jiang, & 
Burgess, (2010) found diabetes associated with frequent hospitalizations either as a direct 
cause or from related complications, especially among those of low income.  Education, 
income, and neighborhood environment are consistent predictors of diabetes disease 
(Garcia et al., 2015; Krishnan, Cozier, Rosenberg, & Palmer, 2010; Lee et al., 2011) 
especially with cumulative exposure (Stringhini et al., 2016).  Exposure to risk factors 
can have a direct and indirect influence on physiological stress and inflammatory 
responses within the body and are thought to explain the differences in disease risk within 
populations (Garcia et al., 2010). 
Untreated diabetes of any type can result in complications that lead to debilitating 
systemic damage (Fowler, 2011).  Complications affecting the gastrointestinal system 
include gastroesophageal reflux, gastroparesis, and diabetes-related neuropathy which 
increase susceptibility to enteric disease (Krishnan, Babu, Walker, Walker, & Pappachan, 
2013).  Mechanisms contributing to an increased risk of infection among those with 
diabetes, include the impact of hyperglycemia and oxidative stress on immune system 
function, the required immune response, and the unique attributes of the infective 
organism including tissue tropism (Gan, 2013).  For example, both Gan (2013) and Peleg, 
Weerarathna, McCarthy, and Davis, (2007) suggested that defects in innate and adaptive 
immunity resulting from impaired neutrophil and T-cell functions increase susceptibility 
to infection among diabetic patients.  Growing evidence also suggests a critical 
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relationship between immune regulation and the intestinal microbiome (Gilbert et al., 
2016; Molloy, Bouladoux & Belkaid, 2012). 
Intestinal Microbiota 
The intestinal microbiota represents a diverse and dynamic ecosystem performing 
essential mechanical and biochemical functions (Gilbert et al., 2016).  Changes or 
disruptions to the composition of this ecosystem can create dysbiosis and subsequent 
illness (Gilbert et al., 2016; Rajilić-Stojanović, 2013).  Within the bacterial ecosystem of 
the intestine, select phyla have been identified as having specific metabolic functions 
(Patterson et al., 2014).   These functions include the breakdown and metabolism of 
indigestible foods, the synthesis of vitamins, and the production of metabolites that 
promote states of health and disease (Patterson et al., 2014; Rajilić-Stojanović, 2013).  
For example, Clostridia species have an essential role in the fermentative digestion 
process and are part of the normal intestinal flora.  However, they also can cause disease 
through the production of toxins.  C. difficile, although a member of the Clostridia 
species, is not commonly found within the normal intestinal flora of humans, due to the 
bacteria’s inability to successfully compete for nutrients in the healthy microbial 
ecosystem of the gut (Voth & Ballard, 2005).  However, disruptions to the microbiota can 
provide an opportunity for organisms such as C. difficile to establish a viable niche 
(Theriot et al., 2013).  The diversity of organisms is an indicator of a healthy microbial 
ecosystem within the gut (D’Argenio, & Salvatore, 2015).  Differences in the distribution 
and diversity of the intestinal microbiota are found to exist among different population 
groups (Escobar, Klotz, Valdes, & Agudelo, 2014; Mueller et al., 2006; Rajilić-
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Stojanović, 2013).  Differences in diet, health behaviors', genetic characteristics, and 
disease states likely explain these variations within the intestinal ecosystem.  Buonomo 
and Petri (2016) suggest that hospitalized patients are at risk for disturbances to the 
diversity and health of the microbiota due to changes in diet, exposure to medications and 
medical interventions.  Hospitalized patients may also have an increased risk of exposure 
to C. difficile spores due to the prevalence of CDI in hospital settings. 
Scientific and technological advances are providing researchers with a 
greater understanding as to the composition and function of the intestinal 
microbiota (Gilbert et al., 2016).  This knowledge includes the role of microbiota 
in the development and maintenance of the immune system.  There is also 
evidence suggesting that the diversity and distribution of the host microbiota 
within the gut plays a role in the onset of non-infectious diseases including 
diabetes (Biedermann & Rogler, 2015).  Diabetes can negatively impact immune 
function and inflammatory responses through several pathways including the 
composition and selective activity of commensal bacteria within the 
gastrointestinal system (Brestoff, & Artis, 2013).  Research into the microbiota 
suggests people with diabetes have differences in both the diversity and the 
distribution of organisms (Larsen et al., 2010; Qin et al., 2012a).  Larsen and 
colleagues (2010) describe differences in the distribution of common intestinal 
bacteria phylum between persons with T2D and non-T2D persons.  In this study, 
researchers found diabetic subjects had a higher abundance of Bacteroidetes (M = 
50.4% vs. M = 35.1%) and significantly fewer Firmicute bacterial groups 
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(M=36.8% vs. M = 56.4%), such as Clostridia, compared to controls.  Studies 
comparing diversity suggest Firmicutes account for 60 to 70% of colonic bacterial 
species and Bacteroidetes 28 to 30% (Yang, Xie, Li, & Wei, 2009; Wang, Ahrné, 
Jeppsson, & Molin, 2005).  Qin et al. (2012a) conducted a complex case-control 
metagenome-wide association study among a Chinese cohort, reporting the 
functional composition of bacteria differed between T2D and controls at the 
genus level.  In this study population, those with T2D were found to have fewer 
butyrate-producing bacteria, which includes Clostridia species, and more 
pathogenic bacteria when compared to non-diabetic controls.  Of the 37 butyrate-
producing bacteria identified from the sample, only 21% were present in the T2D 
group, none of which were among previously isolated species of butyrate-
producing bacteria located in the human colon (Qin et al., 2012b, p.30). 
In a similarly designed study comparing European women, Karlsson et al. (2013) 
identified differences in the composition and structure of fecal microbiota between 
diabetics and non-diabetics.   Karlsson and colleagues used their bioinformatics 
methodology to compare their findings with the Chinese cohort data (Qin et al., 2012a), 
observing similar differences in bacterial functional composition and metabolic pathways 
existed between cohorts.  However, differences in species diversity and abundance were 
noted between the two cohorts perhaps reflecting differences between populations.  
Differences in the distribution of select bacterial groups between those with diabetes and 
non-diabetics could provide an opportunity for C. difficile to proliferate should favorable 
conditions develop.  Favorable conditions include disruptions to established intestinal 
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bacteria, providing an opportunity for C. difficile bacteria to access nutrient sources not 
otherwise available but necessary for replication and growth. 
Sialic Acid 
In the human intestine, sialic acids (Sias), perform several functional roles.  Sias 
are protein-bound monosaccharides characterized by a nine-carbon backbone and have an 
essential role in the regulation of cellular function (Varki & Schauer, 2009).  The most 
abundant Sias in humans is N-acetylneuraminic acid (Varki & Schauer, 2009).  Within 
the mucous layer of the intestine, Sias provide a source of energy and nutrition for both 
commensal and pathogenic bacteria (Vimr, Kalivoda, Deszo, & Steenbergen, 2004).  Sias 
also have a role in regulating host immune function (Varki & Gagneux, 2012).    
Recent studies demonstrate that Sias are utilized by C. difficile as an energy 
source.  Ng and colleagues (2013) showed that C. difficile has the genetic ability to 
catabolize mucosal mucin.  Mucin, a glycoprotein found in intestinal mucous contain Sias 
which bind to the terminal, non-reducing ends of oligosaccharide chains (Vimr et al., 
2004).  However, for C. difficile to expand, the bacteria require an available source of 
free sialic acid (Ng et al., 2013).  This new understanding supports the hypothesis that 
competition for nutrients and disruption to commensal bacteria provides an opportunity 
for C. difficile to develop a niche in an otherwise limiting environment (Britton & Young, 
2014). 
Sialic Acid and Diabetes 
Research into sialic acid (Sias) indicates people with diabetes have higher 
amounts of circulating Sias compared to non-diabetics (Khalili et al., 2013; Schmidt et 
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al., 1999: Varghese, Asha, Celine, & Prasanna, 2015).  Schmidt and colleagues (1999) 
identified an association between increased serum levels of Sias and orosomucoids, a 
glycoprotein to which sialic acid binds, and incident diabetes among a large U. S. cohort.  
A later study by Khalili et al. (2013) analyzing health data from a large Swedish cohort 
also observed a positive relationship between serum Sias and increased risk for diabetes 
and diabetic complications.  Despite limitations for comparison due to differences in 
population groups and the variables included in the analyses, both longitudinal studies 
suggested that people with diabetes have elevated circulating concentrations of Sias.  
Elevated levels of Sias in those with diabetes suggest a potential pathway by which 
people with diabetes could become susceptible to CDI.  For example, disruptions within 
the microbiota, especially to commensal bacteria utilizing Sias as an energy source, could 
increase availability for C. difficile bacteria and the potential for bacterial expansion 
(Huang, Chassard, Hausmann, von Itzstein, & Hennet, 2015; Ng et al., 2013).  The 
association between Sias levels and diabetes are further supported by findings from 
Varghese, Asha, Celine, and Prasanna (2015) who conducted a case-control study 
evaluating the serum concentration of inflammatory markers, including Sias in patients 
with T2D.  Varghese and colleagues found participants with T2D had significantly higher 
levels of serum Sias compared to non-diabetic controls. 
Factors Associated with Disruptions to the Intestinal Microbiota 
Antimicrobial therapy 
 A well-established relationship exists between exposure to antibiotic therapy and 
an increased risk for CDI (Bartlett, Moon, Chang, Taylor & Onderdonk, 1978).  The 
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initial link between CDI and antibiotics was established by Bartlett, Moon, Chang, Taylor 
and Onderdonk (1978) with the identification of C. difficile as a causative agent in 
antibiotic-associated colitis.  Over the past several decades’ researchers have shown most 
classes of antibiotics related to an increased risk for CDI in hospitalized patients (Owens 
et al., 2008).  Variation in reported findings between classes of antibiotic reflects 
differences in the susceptibility patterns and virulence among different strains of C. 
difficile.  For example, Vardakas, Konstantelias, Loizidis, Rafailidis, and Falagas (2012) 
conducted a meta-analysis comparing risk characteristics for BI/NAP1/027 and non-
BI/NAP1/027 C. difficile strains.  Results from their analysis indicate different 
susceptibility and resistance patterns exist between strains.  BI/NAP1/027 strains were 
associated with prior exposure to fluoroquinolones a class of antibiotics previously not 
associated with an increased risk for CDI (Freeman & Wilcox, 1999).  However, 
Clindamycin, a predisposing factor in non-BI/NAP1/027, did not pose a significant 
threat.  These differences support increasing concerns regarding emerging antibiotic 
resistance among select strains of CDI.  Stevens, Dumyati, Fine, Fisher, & Van 
Wijngaarden (2011) found evidence from a large prospective cohort study suggesting 
cumulative exposure to antibiotics over time increases the risk for CDI, making links to 
specific antibiotics challenging.  The mechanism by which antibiotics predispose the host 
to CDI results from the disruption to the host’s normal intestinal microbiota.  This 
disruption enables colonization and expansion of other microorganisms into previously 
occupied niches.  It is also suspected that antimicrobials are not the only medications to 





Proton pump inhibitors 
Proton pump inhibitors (PPI) are a frequently utilized medication in hospitalized 
patients and associated with an increased odd of developing CDI (Barletta & Sclar, 2014; 
Buendgens et al., 2014; Dial, Alrasadi, Manoukian, Huang, & Menzies, 2004).  Exposure 
to PPI medications are thought to contribute to the risk for CDI by altering the diversity 
of the intestinal microbiota (Bavishi, & DuPont, 2011; Imhann et al., 2015; Seto, Jeraldo, 
Orenstein, Chia, & DiBaise, 2014).  Although findings from several meta-analyses 
(Arriola et al., 2015; Deshpande et al., 2015; Janarthanan, Ditah, Phil, Adler, & 
Ehrinpreis, 2012) support an association between PPI exposure and CDI, the role of 
gastric acid suppression in increasing susceptibility to CDI is not entirely understood.  
Some researchers hypothesize that high gastric acidity destroys harmful pathogens 
(Clooney et al., 2016; Janarthanan, Ditah, Phil, Adler, & Ehrinpreis, 2012; Jump, Pultz, 
& Donskey, 2007).  Suppression of gastric acid production then raises the gastric pH and 
increases the bacterial load of pathogens within the gut environment.  An early study by 
Dial, Alrasadi, Manoukian, Huang, and Menzies (2004), found that patients receiving PPI 
medication had an increased risk of CDI compared to those not exposed.  Similar 
findings from a case-control study were reported by the same research team (Dial et al., 
2004), investigating CDI risk while controlling for comorbidities and severity of disease.  
More recently, both Barletta and Sclar (2014) and Buendgens et al. (2014) reported an 
increased risk for CDI associated with PPI exposure among intensive care unit (ICU) 
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patients.  Links between PPI exposure and CDI onset are reported in several meta-
analyses (Deshpande et al., 2015; Kwok et al., 2012; Tleyjeh et al., 2012).  However, 
substantial heterogeneity between these studies was noted as a limiting factor in the 
analysis.  Several studies found increased risk associated with PPI use and concurrent 
antibiotic exposure when compared to PPI use alone (Gordon, Young, Reddy, Bergman, 
& Young, 2016; Kwok et al., 2012).  Recent evidence also suggests that long-term PPI 
use may affect the microbiome.  Clooney and colleagues (2016) reported different ratios 
of Bacteroidetes and Firmicutes between PPI and non-PPI users.  Such differences may 
increase host susceptibility allowing C. difficile bacteria to grow and expand outside of 
the stomach.  This hypothesis is supported by findings from in vivo and cohort studies 
(Imhann et al., 2015; Nerandzic, Pultz, & Donskey, 2009).  Nevertheless, not all studies 
have reported increased risk for CDI associated with PPI use.  Novack and colleagues 
(2014) found no statistically significant risk between PPI exposure and CDI when 
comparing similar levels of disease severity, arguing that previously reported associations 
are the result of differences between comparison groups.  The findings by Novack et al. 
(2014) mirror prior findings by Shah, Lewis, Leopold, Dunstan, & Woodhouse (2000) 
who also found no association between risk for CDI and PPI use when comparing 
samples testing positive for C. difficile toxin, and those that test toxin negative.  
Furthermore, Faleck and colleagues (2016) examined the risks of PPI exposure in 
patients in 14 ICU and found that PPI use did not to increase the risk for CDI nor was it 
found to effect adverse outcomes following CDI infection.  
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Although there is some discrepancy regarding exposure to PPI in hospitalized 
patients, their use has relevance for the diabetic population experiencing gastrointestinal 
complications of altered intestinal motility and gastroesophageal reflux disease.  Such 
complications may place diabetic patients at increased risk for CDI due frequent and 
longer-term usage of gastric acid suppressing medications (Huang & Wang, 2009).  The 
frequent utilization of PPI among hospitalized patients, including those with diabetes is 
important as PPI may confound the relationship between diabetes and CDI, similar to 
antibiotic exposure. 
 Diabetic medications 
Medications used in the management of diabetes, are thought to have some 
impact on the microbiome.  Metformin, an oral antihyperglycemic used in T2D, has been 
found to reduce the risk of CDI in diabetic populations (Eliakim-Raz et al., 2014).  
Eliakim-Raz and colleagues (2014) evaluated the risk of CDI among a sample of 
hospitalized patients, using a case-control design.  The researchers found patients on 
metformin therapy were 42% less likely to develop CDI compared to patients on other 
treatment modalities, such as insulin.  The therapeutic effect of drugs, like metformin are 
thought to come from metabolic alterations within the intestinal microbiome (Forslund et 
al., 2015; Wu et al., 2017).  Forslund et al. (2015) note that medication modalities 
influencing the microbiome could have a confounding effect, and should be controlled 
for in data analysis.  The authors (Forslund et al., 2015) hypothesis was supported with 
differences found in the intestinal microbiome of those taking metformin and those not 
on metformin therapy.  Specific differences included a decreased abundance of butyrate-
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producing organisms in patients with T2D not on metformin, compared to those receiving 
metformin.  Butyrate-producing bacteria are thought to play a protective antimicrobial 
role and depletion of these organisms is associated with an increased risk for CDI 
(Antharam et al., 2013; Schubert et al., 2014).  Studies examining cardiovascular risk in 
T2D have also found patients taking metformin have lower levels of serum sialic acid 
than those on alternative oral antiglycemics (Rahman, Malik, Bashir, Khan & Idrees, 
2010).  
Enteral feeding tubes 
Patients receiving enteral nutrition via feeding tubes have been identified as 
having an increased risk for CDI (Bliss et al., 1998; O’Keefe, 2010).  In a study 
specifically evaluating CDI in tube feed patients, Bliss et al. (1998) found patients 
receiving tube feedings were nine times more likely to acquire CDI than non-tube feed 
patients.  Brown and colleagues (1990) also reported an association between nasogastric 
(NG) tubes and increased risk for CDI in a case-control study.  Although Brown, Talbot, 
Axelrod, Provencher & Hoegg (1990), found patients with NG tubes to have 28 times 
greater risk for CDI, the small sample size, and differences noted between case and 
control patients makes these finding less reliable.  For example, more than 25% of 
controls came from the obstetrics and gynecology services which likely have healthier, 
and younger female patients.  Recent studies (van Werkhoven et al., 2015; Wijarnpreecha 
et al., 2016) have continued to report an increased risk for CDI associated with the use of 
gastric and nasogastric feeding tubes.  However, smaller effect sizes are reported 
compared to earlier studies (Brown, et al., 1990; Bliss et al., 1998).  In contrast, Lin et al. 
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(2015) conducted a prospective cohort study examining risk factors for CDI in a 
Taiwanese population and found tube feeds were not a statistically significant risk factor 
for developing CDI in both bivariate and multivariate analyses.  Larentis, Rosa, De 
Santos, and Goldani (2015) found no association between tube feeds and CDI in bivariate 
analysis, but the authors did find tube feeding an independent risk factor associated with 
poor outcomes in CDI.  
Several mechanisms for the increased risk for CDI with the use of feeding tubes 
have been proposed.  These include the transfer of C. difficile bacteria by healthcare 
workers during routine manipulation of the tubes (Best, 2008; Bliss et al.,1990; Brown et 
al., 1990), and the potential contamination of enteral formula from the environment (Bliss 
et al., 1998; Mutters et al., 2008).  There are also some indications that the type of enteral 
formula can alter the gut microbiota, promoting the expansion of bacteria, including C. 
difficile in the gut (Iizuka et al., 2004).  O’Keefe (2010) notes that elemental and low-
residual formulas, while readily absorbed in the small intestine lack the complex 
carbohydrates and fiber that support a diverse and protective microbiota within the colon.  
Disruptions to the microbiota from these types of formula can also provide an 
opportunity for C. difficile to proliferate within the colon and cause disease (O’Keefe, 
2010). 
Prior healthcare location 
The risk of CDI among the AR population could be affected by previous exposure 
to healthcare settings, with patients exposed to risk factors, such as antibiotics and 
contaminated environments.  Information regarding the prevalence of CDI or 
39 
 
colonization in the AR environment is limited.  Marciniak and colleagues (2006) 
investigated the prevalence of C. difficile colonization among rehabilitation patients 
admitted from an acute care setting.  Findings from this case-control study found 16% of 
patients were colonized with C. difficile.  However, evidence indicating prior 
colonization as predictive of developing CDI was inconclusive.  Other studies examining 
the transmission of CDI among different hospital settings, reported higher estimated rates 
of transmission among residents in long-term care (LTC) settings compared to the acute 
hospital or the community (Durham, Olsen, Dubberke, Galvani & Townsend, 2016).  
Ricciardi, Nelson, Griffith, and Concannon, (2012) also suggest that higher rates of CDI 
among LTC residents result in an increase burden of CDI in acute care hospitals.  
However, a recent study by Ziakas et al. (2016) among a national sample of LTC 
residents, found that almost two-thirds of those diagnosed with CDI had a been 
hospitalized within the previous 30 days or had a hospital discharge within the last 90 
days.  Similar findings were reported by Zarowitz, Allen, O’Shea, and Strauss (2015), 
who evaluated a large national sample of nursing home residents.  Results from this 
research found only 21% of CDI cases were nursing-home acquired, and the majority, 
85%, of cases were admissions from acute care hospitals.  Although patients often move 
between healthcare settings, most admissions to post-acute settings are from acute care 
hospitals (Hunter et al.,2016; Zarowitz et al., 2015; Ziakas et al., 2016).  In addition, 
characteristics among cases, such as exposure to antimicrobials, underlying health 
conditions, and older age are consistently identified across various healthcare settings 
(Hunter et al.,2016; Zarowitz et al., 2015; Ziakas et al., 2016).  Different healthcare 
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settings could impact the exposure burden of CDI.  However, limitations noted in 
previous research regarding an absence of data from prior hospitalizations, time from 
exposure to infection, and sample size (Marciniak, Chen, Stein, & Semik, 2006; Mylotte, 
Russell, Sackett, Vallone, & Antalek, 2013) reduces the value of adjusting for location in 
the analysis. 
Individual Host Factors 
Age 
Evidence of a correlation between advanced age and an increased risk of CDI 
have been published both in the U.S. and globally.  Lessa et al. (2015) reported 
population estimates of incidence HAI-CDI in the U.S. among those 65 years of age and 
older of 481.5 per 100,000 persons compared to only 83.1 per 100,000 persons aged 45 to 
64 years.  Similarly, an European population-based surveillance study of HAI- CDI found 
persons over 65 years incurred three times the risk of CDI compared to those of younger 
age (Bauer et al., 2011).  Smaller studies have also reported older adults experience 
higher risk for CDI and increased disease severity.  Patel, Wieczorkiewicz, and Tuazon 
(2016) found advanced age, defined as over 70 years, associated with a 2-fold increased 
risk of developing severe CDI disease.  Lee et al. (2016) also reported more severe illness 
among hospitalized Korean patients 65 years and older compared to those under 65.  
Using a prospective study design, Kurti et al. (2015) described CDI incidence in an 
Eastern European hospital population.  Although they reported 83% of CDI cases were 
over 60 years of age, age alone was not a significant risk factor.  Instead, an association 
with disease severity and mortality was identified.  The severity of illness among those 
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with CDI is likely affected by multiple factors, including different bacterial strains.  
Miller et al. (2010) found select C. difficile strain associated with worse outcomes.  
Disease severity and C. difficile attributable mortality did increase with age, particularly 
in those over 60 years.  However, the very old experienced poor outcomes regardless of 
C. difficile strain. 
Race and ethnicity 
Disease and health-related outcomes are frequently examined within the context 
of race and ethnicity in the U.S.  Understanding the role of race and ethnicity and social 
determinants in health distribution is complex (Ichiro, Daniels, & Robinson, 2005).  
Reports of racial and ethnic differences in CDI incidence and outcome measures suggest 
that some level of health disparity may exist.  Differences include higher rates of CDI in 
White compared to non-Whites population groups.  Lessa et al. (2015) analyzed 
surveillance data from ten States across the U. S. and found rates for both incidence and 
recurrent CDI higher in Whites compared to non-Whites.   Also, Mao, Kelly, and Machan 
(2015) and Olanipekun, Salemi, de Grubb, Gonzalez, and Zoorob (2016) examined the 
effect of race on CDI.  Using secondary data from the Healthcare Cost and Utilization 
Project Nationwide Inpatient Sample (NIS), both studies reported higher rates of 
infection among Whites compared to other racial and ethnic groups.  Additionally, Mao 
and colleagues found Whites more likely exposed to antibiotics than other races.  
Findings from a study by Bakullari et al. (2014) suggest HAI occurs more frequently 
among Asian and Hispanic populations.  Asian populations also experienced a higher 
occurrence rate of CDI, compared to White, non-Hispanic groups (0.5% vs. 1.1%) in a 
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Medicare population.  Murphy, Avery, Dubberke, & Huang (2012) also reported an 
increased probability of healthcare-onset CDI among Asians compared to Whites.  
However, non-Hispanic Whites were more likely to experience CDI following discharge.  
Although not evaluated, such findings may reflect differences in access to care in the 
outpatient setting (Murphy et al., 2012).   In contrast to other studies, Freedberg et al. 
(2013) found Black race associated with an increased risk for recurrent CDI when 
evaluating PPI exposure.  In this hospital-based cohort, the multivariate analysis found 
Black race associated with increased risk for CDI compared to Whites.  Differences in 
CDI outcomes related to race and ethnicity indicate multiple factors and pathways 
contribute to risk.  Bakullari et al. (2014) suggested that language barriers could 
adversely impact some population groups when hospitalized.  Other variables such as 
socioeconomic, environmental and social factors may also contribute increased risk for 
CDI (Freedberg et al., 2013; Lessa et al., 2015).  The increased risk for Caucasians found 
in large inpatient population datasets, may reflect greater access and exposure to 
healthcare settings and antibiotics compared to other minority groups. 
Obesity 
High BMI has been linked to both the risk of developing diabetes and CDI 
(Bishara et al., 2013; Leung, et al., 2013; Leung, Carlsson, Colditz & Chang, 2016; 
Nguyen, Nguyen, Lane, & Wang, 2011).  The CDC (2016) classifies a normal or healthy 
BMI between 18.5 and 24.9 and obese, as a BMI equal or greater than 30.  Nguyen and 
colleagues (2011), using data from the National Health and Nutrition Examination 
Survey found 49% of diabetics were also obese based on their BMI.  Ganz et al. (2014) 
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conducted a case-control study using data from a large U.S. health system and found the 
risk for T2D between 2.5 and 5 times greater among those within the obese BMI 
categories.  Leung, Carlsson, Colditz, and Chang (2016) also reported a strong 
association between obesity and risk for diabetes using population-based health 
utilization data.  There is also evidence suggesting a link between obesity and the risk of 
developing CDI.  Bishara et al. (2013) conducted a case-control study testing the 
hypothesis that obese persons may have increased susceptibility to CDI compared to lean 
persons, based on potential differences in the gut microtia between the groups.  Findings 
from their multiple regression analysis found obesity an independent risk factor in CDI 
among this study population.  Leung and colleagues (2013) also investigated the 
relationship between obesity and the risk for CDI among hospitalized patients.  Results 
from their retrospective analysis suggest an association between obesity and CDI, among 
those without prior exposure to healthcare facilities after controlling for antibiotic use.  
No significant relationship was found between obesity and healthcare-associated CDI.  
However, the small sample size suggests the study may not have had adequate power to 
detect a statistically significant association. 
Disease severity 
A potential confounder in the relationship between diabetes and CDI is the 
severity of diabetes.  Diabetes can adversely affect the body’s vascular systems (Fowler, 
2011).  The resulting damage to the macro and microvascular systems contribute to 
complications such as cardiovascular disease, peripheral vascular disease, stroke, 
nephropathy and retinopathy (Fowler, 2011).  Complications of diabetes are also 
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associated with increased morbidity and mortality (Steiner & Friedman, 2013).  Steiner 
and Friedman (2013) examined comorbidities among hospitalized patients using data 
from the NIS.  The analysis found diabetes was a frequent discharge comorbidity among 
those with three or fewer underlying conditions across all age groups.  Of interest, the 
proportion of adults with four or more chronic diseases was highest for Whites, while 
Hispanics had the least.  The number of presenting complications and risk for CDI could 
reflect the overall health status of patients, measured as the number or the type of health 
complications on admission.  Wenisch et al., (2012) investigated risk factors for severe 
CDI in a small sample of hospitalized patients, noting more than 60% of the sample had 
moderate to severe underlying diseases based on the Charlson commodity index.  
Multivariate analysis found only diabetes, chronic kidney disease and chronic pulmonary 
disease associated with increased risk of severe CDI, and diabetes associated with higher 
odds of infection.  The authors reported no association between disease severity and 
increased age.  A limiting factor in the interpretation of these results is the potential for 
inadequate power due to the small sample size, especially when correlations between 
increasing age and disease severity have been identified (Kyne, Sougioultzis, McFarland, 
& Kelly, 2002; Murphy et al., 2012).  Murphy et al. (2012) identified individual 
characteristics predictive for CDI included age and diabetes in both bivariate and 
multivariate analysis.  Tartof and colleagues (2014) also reported higher proportions of 
CDI cases among those with diabetes and severe diabetes in addition to 14 additional 
underlying conditions.   
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Most studies examining CDI address the potential confounding of underlying 
conditions on the outcome.  However, few studies differentiate between the diabetes 
severity as was done in the study by Tartof et al. (2014).  Interestingly, there is evidence 
suggesting that diabetes may be protective against CDI.  Stewart and Hollenbeak (2011) 
analyzed NIS data from 2007, evaluating risk factors associated with excess attributable 
costs and mortality between those with and without CDI.  In their analysis, both diabetes 
and diabetes with complications resulted in lower odds of dying compared to those 
without CDI.  This unexpected finding may reflect less virulent strains circulating in 
hospitals during the sampling period or less precise testing methods than currently 
available.  In addition, the use of administrative databases poses limitations related to the 
availability of clinical data such as diagnostic results and medications specific to 
individual patients. 
Clostridium difficile Infection and Diabetes 
Few studies have examined the association between diabetes and CDI despite the 
increasing prevalence of both diseases.  A recently published population-based study 
examining CDI among patients with T2D reported an overall prevalence of CDI among 
hospitalized patients with T2D of 6.8 per 1000 acute care discharges (Olanipekun et al., 
2016).  Thus, people with diabetes could account for a large number of cases when 
compared to national estimates of 13.8 CDI cases per 1000 discharges (Jarvis, Schlosser, 
Jarvis, & Chinn, 2009).  Olanipekun et al. also reported a positive correlation between 
CDI and increased mortality, duration of hospitalization, and cost.  Although Olanipekun 
et al. reported on findings from a large randomized cohort of hospitalized patients, the 
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sample excludes post-acute patients in rehabilitation and long-term acute care hospitals.    
However, with an estimated 76% of hospitalized patients discharged to post-acute 
settings (Burke et al., 2015), the prevalence of CDI in the diabetic population was likely 
underestimated.  Shakov, Salazar, Kaqunye, Buddora, & DeBan (2011), found people 
with diabetes had an increased for recurrent CDI.  Since the outcome of interest was 
recurrent disease, no association between incident CDI risk and diabetes was evaluated.  
Limited evidence suggests diabetic patients who develop CDI may have unique 
characteristics.  For example, Hassan, Rahman, Huda, Wan Bebakar and Lee (2013) 
found diabetic patients with CDI were younger and diagnosed with sepsis, thus more 
likely to have received antibiotics.  However, the validity of their results is limited by the 
small number of CDI cases included in the analysis.  More recently, Olanipekun et al. 
(2016) analyzed data from a large U. S.  national sample, and found differences in race 
and income when comparing those with diabetes and CDI and diabetics without a 
diagnosis of CDI.  Similar to other reported studies (Mao, Kelly, and Machan, 2015), the 
Olanipekun et al. (2016) study found a higher proportion of CDI occurring in Whites.  
Differences associated with income were also noted, with a larger proportion of those 
with CDI having higher household incomes while lower income was positively related to 
an increased length of stay, associated costs, and risk for mortality.  The differences 
noted by Olanipekun et al. may reflect the impact socioeconomic status and overall health 
status have on those with diabetes. 
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Summary and Conclusions 
Investigations into the relationship between diabetes and CDI have been 
observational and most often using historical data.   The inability to infer causation is an 
inherent weakness of observational studies (Rothman, Greenland, Poole, & Lash, 2008), 
as even well-designed observational studies remain vulnerable to unexpected or unknown 
confounding variables.  Within the reviewed literature, differences in sample populations 
and sample size were frequent, and likely explained the variation in reported outcomes.  
For example, sample sizes ranged from 159 patients in a single hospital setting (Hassan et 
al., 2014) to over 3,000,000 patients included in a national inpatient database over a ten-
year period (Olanipekun et al., 2016).  Differences in geographical locations and 
healthcare settings also existed, although the majority of studies included hospitalized 
patients from acute care settings.  Some researchers used large population-based samples 
to examine CDI outcomes providing a nationally representative population from which to 
interpret and extrapolate findings.  Population-based samples drawn from national data 
sources often provide access to large samples which strengthen the credibility of the 
results.  However, such samples have limitations.  For example, the NIS database 
contains data from a large number of participating community hospitals yet, excludes 
data from post-acute hospital settings such as rehabilitation and long-term care facilities 
(Healthcare Cost and Utilization Project [HCUP], 2016).  Other limitations of 
administrative databases are the accuracy and availability of data extracted from medical 
records.  Differences between studies also existed regarding the measurement of 
variables, in particular, comorbidities.  The most frequently used measure of disease 
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severity identified in the literature was the Charlson Comorbidity Index, although 
variation in the presentation of included variables was noted.  Other strengths identified 
from this review include consistencies in the diagnosis of CDI, with studies using similar 
testing processes and definitions. 
Conclusion  
This review of the literature addressed several major themes related to diabetes 
and CDI.  The role of the intestinal microbiota is shown to have a strong influence in 
regulating the immune system, as well as limit available niches for pathogenic bacteria.  
The development of commensal flora and balanced ecosystem within the intestinal 
environment depends on the availability of essential nutrients and the organism’s ability 
to access and utilize them.  Research into the role of Sias as a nutrient source for C. 
difficile bacteria and as an indicator of inflammatory processes in persons with diabetes 
raises the question as to whether diabetes poses an increased risk for CDI.  Few studies 
have specifically examined the relationship between diabetes and CDI.  Most research 
into CDI outcomes include diabetes as a comorbidity measure related to disease severity, 
rather than a primary risk factor.  Exposure to antibiotics adversely affects the risk for 
CDI through organism resistance and disruption to the commensal bacteria of the gut.  
Such disturbances, in turn, support the opportunistic expansion of C. difficile bacteria.  
Exposure to PPI medications may also contribute to CDI, although the mechanisms for 
this association are not well understood.  Host characteristics such as age, race, 
underlying disease states and disease severity also appear to contribute to CDI.  Despite 
the myriad of research related to CDI, understanding the determinants contributing to 
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disease onset remains unclear.  In addition, little research appears to focus on the impact 
of CDI among hospitalized patients with diabetes.  This literature review has identified 
possible mechanisms unique to diabetic patients contributing to an increased risk for CDI 
in this population. 
My study evaluating the relationship between diabetes and CDI addresses the 
need for data regarding CDI in the diabetic population.  This study also fills a gap in the 
literature regarding CDI risk factors in the post-acute setting.  Addressing the deficits 
identified in the literature is an important step for CDI prevention.  The following chapter 
discusses the design and methodology elements of this study, including a description of 




Chapter 3: Research Method 
Introduction 
A case-control research design was used to answer the research questions 
regarding the relationship between diabetes and CDI, and the presence of modifiable risk 
factors among diabetic patients.  The main purpose of this study was to assess the 
association between diabetes and CDI among the acute-rehabilitation population.  
Evaluation of this relationship included controlling for select environmental and host 
characteristics.  For this study, the outcome variable was the presence of CDI and the 
independent variable diabetes.  Control variables include age, ethnicity/race, gender, 
admission diagnosis, health status, functional independence, and diabetes disease 
severity.  The second aim of this study was the identification of environmental and host 
characteristics sensitive to modification in the diabetic population.  Other independent 
variables of interest include antibiotic use, gastric acid suppressants, diabetic 
management, BMI, and the presence of gastric feeding tubes.  
Chapter three presents the proposed methodology to answer the aforementioned 
research questions.  This chapter describes the research design and supporting rationale.  
Variables included in the analysis are presented and operationalized.  This chapter also 
describes the sampling plan, the data collection methods, the ethical considerations 
pertinent to this research study, and a discussion regarding potential threats to the 
external and internal validity of the proposed study.  Finally, the methods for the 
statistical analysis and testing of hypotheses are described.  
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Research Design and Rationale 
Independent and dependent variables of interest are diabetes and CDI, 
respectively.  Variables acting as potential confounders include antibiotics, obesity and 
PPI.  Persons with diabetes may experience greater exposure to antibiotics, thereby 
increasing their risk for CDI.  Likewise, diabetics may also have increased exposure to 
PPI medications resulting from disease-related complications, and there is evidence 
suggesting PPI may increase the risk of CDI.  Potential confounders include patient 
comorbidities which could influence the strength of the relationship between the 
independent and dependent variable, including obesity.  Age is a potential confounding 
variable associated with both increased risk of diabetes and CDI.  Covariates include 
ethnicity/race, gender, admission diagnosis, duration of hospital stay, diabetes disease 
severity, obesity, and underlying co-morbidities. 
Case-control designs support the evaluation of exposure-disease associations and 
allows for retrospective comparison of factors which may contribute to the risk of disease 
(Szklo & Nieto, 2014).  The comparison between cases and controls can generate 
estimates of exposure prevalence and risk factors in the source population (Rothman, 
Greenland & Lash, 2008, p.112).  Case-control studies support the use of secondary data 
and for use in diverse and dynamic populations such as those found in hospital settings 
(Carlson & Morrison, 2009; Vandenbroucke & Pearce, 2012).  A defining characteristic 
of case-control studies is the selection of cases based on the outcome of interest, which 
for this study is CDI.  The case-control design is also useful when studying infrequent or 
rare outcome events.  Although CDI is an HAI of concern, the estimated incidence of 
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CDI among the acute care settings is less than 20% (Magill et al., 2014) with an 
estimated frequency of 15 % among the AR population (Mylotte, Graham, Kahler, 
Young, & Goodnough, 2000). 
Methodology 
Population 
A total of 7953 discharge records were identified for the study period, August 01, 
2009, and September 30, 2015, with 217 records having an ICD-9 code for CDI. The 
final number of cases meeting the inclusion criteria was 102.  Both cases and controls 
came from the same source population.  The source population included all patients 
discharged from a New Mexico free-standing urban AR hospital during the defined study 
period.  This acute inpatient rehabilitation hospital accepts patients from throughout the 
State with an estimated 1200 discharges per year.  The average length of stay at this 
hospital is 14 days.  Patients access the AR setting to improve their functional 
independence while still receiving inpatient hospital care, allowing patients to return to 
their homes and communities. 
Sampling and Sampling Procedures 
Participant selection 
The following plan outlines the strategies used to increase the representativeness 
of the participants in this study and reduce sampling errors.  For this study, all available 
cases, and a sample of eligible controls was drawn from the same target population.  A 
positive laboratory test for C. difficile toxin during an episode of hospitalization was 
needed to meet the criterion as a case.  Randomly selected patients discharged during the 
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study time frame without a positive test for C. difficile toxin were eligible for inclusion in 
the control group.  The exclusion criterion for both cases and controls were discharged 
patients under the age of 18, and those patients receiving treatment for CDI at the time of 
admission as noted in the admission history and physical.  
The target population consisted of all discharged patients from the research site 
during specified study period.  The following procedures describe the selection of both 
cases and control samples.  A query of the facility administrative data was used to 
generate a list of all patients discharged during the study period.  Information requested 
for this query was limited to discharge date, ICD-9 code discharge diagnoses, and 
medical record number.  ICD-9 code 089.45 provided the initial screen to identify cases 
of CDI.  The medical record number was necessary to locate the correct medical record 
for review in the absence of an electronic medical record.  Use of ICD-9 codes to query 
nosocomial CDI has been used previously with good sensitivity, but limited specificity 
when compared to laboratory results (Scheurer, Hicks, Cook, & Schnipper, 2007).  To 
limit the potential for misclassification, laboratory results were reviewed to confirm the 
CDI diagnosis.  All verified CDI cases meeting the inclusion criteria were included in the 
case group.  For each case, two controls were selected from the list of discharged 
patients.  The discharge list was organized by date and controls selected using the 
medical record number located above and below the case subject.  In the event, 
consecutive cases were identified, the next available units above and below the cases 
were selected, maintaining the 1:2 ratio.  This method of control selection reduced 
potential sampling bias by increasing the likelihood that controls were from the same 
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population that produced the cases. 
A priori power analysis 
This research study used a fixed sample capturing all eligible CDI cases identified 
during the study period.  An estimated 25 cases of hospital-associated CDI were reported 
at the facility each year.  This estimate was based on historical infection control 
surveillance reports.  Prior to data collection, a priori analysis of the expected power was 
conducted.  Information from the power analysis provided an estimation of type 2 error 
associated with a sample of this size.  OpenEpi software (Dean, Sullivan, & Soe, 2002) 
was used to generate the power analysis for a two-tailed test with the estimated sample 
size of 125cases during the originally proposed 57-month study period of January 1, 2011 
through September 30, 2015.  The level of significance was set at 5%, with a 95% 
confidence interval.  An odds ratio of 2 was estimated from the proportion of diabetes 
exposure among cases and controls obtained from previously reported data (Weeks, 
2009, Meng, Pickett, Babey, Davis, & Goldstein, 2014).  Review of the literature 
suggested the estimated proportion of hospitalized patients with diabetes ranges from 
18% in the rehabilitation setting (Weeks, 2009), to almost 20% in the acute care settings 
(Fraze, Jiang, & Burgess, 2010), although estimates of 30% have also been reported 
(Meng et al., 2014).  Additional selected studies reported that 24 to 38 % of CDI cases 
also had a history of diabetes (Abdelsattar et al., 2015; Hunter et al., 2016; Tartof et al., 
2014; Zilberberg et al., 2014).  Based on this reported data, the percent of exposure 
among cases was estimated at 30%.  The power analysis calculation indicated that the 
estimated sample size is unlikely to achieve the desired 80% power (Table 1). 
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Table 1  
Results of A priori Power Analysis 
Input Options Input Data 
Two-sided confidence interval (%) 95 
Number of cases 125 
Percent of exposure among cases (%) 30 
Number of controls 250 
Percent of exposure among controls (%) 18 
Odds Ratio 2 
Power: Normal approximation 74.28% 
 
Note.  Power analysis generated for unmatched case-control study using OpenEpi statistical software 
(Dean, Sullivan, & Soe, 2002).  Number of cases is estimated from an estimated number of CDI cases 
occurring each year at facility. 
 
 
Data Collection Methodology 
The initial data collection study period from January 1, 2011, through September 
2015 found 140 records coded for CDI.  However, 71 did not meet the inclusion criteria.   
Exclusion criteria included receiving treatment for CDI at time of admission (n = 40), or 
laboratory test results negative for C. difficile toxin.  Twenty-four records coded for CDI 
were negative for toxin, although positive for antigen, and seven records were miscoded 
with either negative results reported or no documented test result.  The number of actual 
cases (n = 69) was unable to provide adequate power, increasing the risk of a Type II 
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error.  Thus, the study period was extended to include an additional 24 months, following 
approval from the Walden University IRB.  The second set of data found a total of 77 
potential cases.  Unfortunately, access to discharged records was restricted to patients 
discharged after August 1, 2009, resulting in the removal of 31 cases and 50 controls.  Of 
the remaining available CDI coded records (n = 46), one was excluded due as unable to 








Data Extraction Procedures 
The analysis dataset for this case-control study was constructed utilizing a 
secondary data source.  Permissions to build a data set from information documented in 
the hospital medical record was granted by the Chief Executive Officer at the study site.  
The permission process included review of the dissertation proposal by the facility’s 
leadership and risk management department.  In addition to permissions obtained from 
the healthcare facility, Walden University Institutional Review Board (IRB) approval was 
obtained prior to commencing data collection.  
Once the study participants were selected, the medical record for each subject was 
reviewed for study eligibility.  The medical record provided documentation regarding the 
medical history, and clinical care of patients, by trained healthcare providers.  A manual 
chart review of each eligible record was conducted, and data for each study variable 
extracted and recorded on a standardized data collection form.  A new data collection 
form was completed for each subject and identified using a unique study code.  
Demographic variables collected included age, sex, ethnicity, and length of stay.  Care 
was taken to extract only that data necessary to answer the research questions and 
avoided the collection of any patient identifying information.  Use of a data collection 
tool supports a standardized approach to data abstraction and increases the internal 
validity and reproducibility of the study (Gregory & Radovinsky, 2012).  Data from the 
collection tool was inputted into an Excel spreadsheet (www.microsoft.com), creating the 
data set for statistical analysis.  A manual process for review and data extraction was 




Instrumentation and Operationalization of Constructs 
Instrumentation 
Patient co-morbidities and disease complications in this sample were measured 
using the modified Cumulative Illness Rating Scale (CIRS).  The CIRS as a measure of 
comorbidity has been used previously in rehabilitation related research, including 
orthopedic, stroke and burn patient populations (Bejor, Ramella, Toffola, Comelli, & 
Chiappedi, 2013; Giaquinto et al., 2001).  It combines two indexes, a cumulative index 
and a severity index (Linn, Linn & Gurel, 1968; Salvi et al., 2008).  Researchers have 
also found the CIRS a valid and reliable tool for research use (de Groot, Beckerman, 
Lankhorst, & Bouter, 2003).  The CIRS rates 13 items organized by body system, and 
uses a 5-point severity rating, ranging from no impairment (0) to extremely severe 
impairment (4).  Summing of all items provides an overall impairment measure.  
Limitations with this scale include the element of clinical judgment in assigning severity 
scores.  However, having defined parameters can improve the reliability of severity 
scoring.  
The severity of diabetes disease was measured using the Diabetes Complications 
Severity Index (DCSI) (Young et al., 2008).  This 13-point complication index provides a 
measure of risk for adverse diabetes outcomes using the type and number of 
complications present (Young et al., 2008).  Complications included in the DCSI are 
cardiovascular disease, metabolic, nephropathy, neuropathy, peripheral vascular disease, 
retinopathy, and stroke.  The DCSI was developed using laboratory data and ICD-9 
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codes, with each complication group categorized into three levels (no abnormality = 0, 
some abnormality = 1, severe abnormality = 2) depending on the presence and severity of 
the complication.  The DCSI was developed and validated using 4229 participants 
enrolled in a larger longitudinal prospective population-based cohort in the U. S. (Young 
et al., 2008).  The DCSI was selected for this study as it specifically measures the 
severity of complications in a diabetic population and addresses a broad range of 
complications associated with the disease.   
A third instrument used to evaluate the functional independence of patients 
admitted to AR was the Functional Independence Measure (FIM).  In the U.S., the FIM 
provides both a measure of disability at admission and the functional gains following 
inpatient medical rehabilitation.  Developed in the 1980’s, the FIM is a product of the 
American Academy of Physical Medicine and Rehabilitation and the American Congress 
of Rehabilitation Medicine.  The FIM software is available and licensed through Uniform 
Data System (UDS) for Medical Rehabilitation (www.udsmr.org).  The extensive use of 
the FIM in the U.S. is in part due to the quality reporting requirements for inpatient 
rehabilitation facilities receiving reimbursement through CMS (Granger, 2013).  
Documentation of the admission and discharge FIM is recorded in the medical record for 
later extraction and upload to the UDS database.  
The FIM instrument consists of 18 items; thirteen items measure motor tasks and 
five items address cognition (Rehabilitation Institute of Chicago [RIC], 2013).  The 
patient’s level of independence is evaluated by certified clinicians.  The measure of 
independence is, based on an individual’s ability to complete defined tasks.  Tasks are 
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rated on a 7-point ordinal scale, where 1 is complete dependence requiring total 
assistance and 7 is complete independence.  The level of function is calculated from the 
total score which ranges from a minimum score of 18 to maximum score of 126 (RIC, 
2013).  The FIM assessment is conducted at admission and repeated at discharge. 
The FIM has been shown to have high internal consistency and validity across a 
range of rehabilitation diagnoses, with strong construct validity (RIC, 2013).  Dodds and 
Colleagues (1998) evaluated internal consistency for a general rehabilitation population, 
reporting an admission FIM using Cronbach’s α of .93, and a discharge FIM of α = .95.  
More recent evaluation of relatability and validity of the FIM in rehabilitation burn 
patients reported overall Cronbach’s α of .96 for motor scales and .97 for cognitive 
scales, and strong construct validity scalability coefficients > 0.5 (Gerrard et al., 2013).  
Although studies indicate strong internal consistency, variability in routine use among 
personal, and the potential for missing data may reduce the internal validity. 
Operationalization of Variables 
The following table (Table 2) describes each of the variables, the level of 




Table 2  
Operationalization of Study Variables 
Variable Type of  
Variable 
Operational Definition Values 
CDI DV Positive assay or PCR for C. 
difficile toxin laboratory 
results 
1 = Yes 
0 = No 
Diabetes IV Documentation of diabetes 
in the admission H & P 
1 = Yes 
0 = No 
Admission 
diagnosis 
IV Rehabilitation admission 
diagnosis group as defined 
by CMS 
 
1 = stroke, 2 = spinal cord injury, 3 
= multiple trauma, 4 = brain injury, 
5 = amputation, 6 = burns, 7 = 
lower limb fractures, 8 = complex 
orthopedic conditions, 9 = 
musculoskeletal, 10 = neurological 
disorders, 11 = debilitation 
Age 
 
IV Age of participant at the 
time of admission.  





Documented sex 1 = Female 
2 = Male 
Ethnicity IV 
 
Documented ethnicity  
 
1 = Caucasian 
2 = Hispanic 
3 = Black/African American 
4 = Asian 
5 = Native Hawaiian or Other 
Pacific Islander 
6= American Indian,  
7 =Other 
Blank = unknown; Missing 
Antibiotics IV Documentation of 
antibiotics received by 
participants in prior 30 days 
before discharge  
1 = Yes 
0 = No 
Height IV Documented height on 
admission (Used to 
calculate BMI variable) 
Continuous variable in inches 
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Variable Type of  
Variable 
Operational Definition Values 
Weight IV Documented weight at time 
of admission (Used to 
calculate BMI variable) 





Body mass index, calculated 
from documented height 
(inches) and weight 
(pounds) 
1 = Underweight = <18.5 
2 = Normal weight = 18.5–24.9  
3 = Overweight = 25–29.9   
4 = Obesity = BMI of 30 or greater 
Comorbidities IV Other disease states 









Comorbidities assessed by 
body system to Provides a 
measure of whole person 
impairment based on the 
sum of 13 system items 





score (DCSI)  
 
 
IV Evaluates presence and 





vascular disease, Metabolic 
Score range 0 to 13 
Diabetes Control 
 
IV Prescribed method of 
controlling blood glucose 
levels 
1 = diet 
2 = oral 
3 = insulin 
4 = both insulin and oral 
Tube feeding IV Presence of a feeding tube 0 = No 
1 = Yes 
 
FIM IV Functional Independence 
Measure assessed on 
admission 






Documentation of Proton 
pump inhibitor drug 
administered in prior 30 
days before discharge 
0 = No 
1 = Yes 
  
Note. DV = dependent variable; IV = independent variable 
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Data Analysis Plan 
IBM SPSS Statistics [Version 23.] software was used to conduct all analysis of 
the data.  The data was cleaned and frequencies examined to identify outliers.  For 
variables with outlying values, the associated data collection form was reviewed for 
errors in data entry and corrected.  Distribution of continuous variables was examined for 
assumptions of a normal distribution.  Data cleaning techniques to limit the effect of 
potential errors included replacing outlying values with the next highest score that is not 
an outlier (Field, 2013).  This method avoided deletion of data from the analysis and 
thereby reduction of the sample size.  One record was removed from the dataset due to 
the substantial number of variables with missing data.   
Research Questions 
Research Question 1: Is there any relationship between diabetes and CDI among 
hospitalized patients in the acute rehabilitation (AR) setting? 
Research Question 2: Are modifiable environmental (antimicrobial and 
medication exposures) and host characteristics (behaviors, BMI, diabetes management) 
associated with CDI among hospitalized diabetics in the AR setting? 
Statistical Tests and Procedures 
Descriptive statistics were measured and examined to describe characteristics of 
the sample.  The distribution of continuous variables was assessed using measures of 
central tendency and dispersion including the mean and standard deviation.  Categorical 
data was presented as proportions.  Differences between groups were tested using the 
independent t-test.  Had data not followed a normal distribution, non-parametric tests 
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such as the Mann-Whitney U or Wilcoxon Rank Sum test would have been employed.  
Categorical variables were analyzed using Person’s Chi-square (χ2) to measure the 
association between two groups.  
Exploratory analysis of the data included evaluating variable frequencies, 
assessment of interactions between the exposure variable and covariates, and assessment 
of potential confounders.  Continuous independent variables were assessed for linearity 
and multicollinearity.   In response to the small fixed sample size, independent variables 
were transformed into dichotomous variables.  This decision was made following review 
of the cross-tabulated frequencies to ensure the assumption of expected frequencies was 
not violated with all cells having a minimum frequency of five.  Assessment of effect 
modifiers and confounders was based on analysis of the literature presented in chapter 2. 
Research Question 1 
To test the relationship between diabetes and CDI Pearson's chi-square test was 
conducted.  To adjust for potential confounding variables, hierarchical multiple logistic 
regression modeling was used to test the study hypotheses.  Hierarchical backward 
elimination was used (Kleinbaum & Klein, 2010) to determine the best estimate of the 
relationship.  The initial model (Table 5) included all potential confounding variables and 
the effect modifying term to create a baseline model for comparison from which to assess 
which variables could be eliminated from the final model.  To determine the best fitting 
model variables were excluded in turn from the model and model refitted.  Initial models 
included all covariates.  Only those risk factors found significant (p ≤ 0.05) or deemed 
relevant based on previous research were retained in the final models.  Results of both 
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bivariate and multivariate regression models are reported as odds ratios.  Changes to the 
exposure variable, diabetes, were assessed for change in odds ratio and precision as noted 
by 95% confidence interval.  Null hypothesis testing was set at the 5% probability level 
(p-value ≤ 0.05), two-tailed.  Estimates of population parameters had a 5% margin of 
error, and are reported as 95% confidence intervals. 
Research Question 2 
Multivariate logistic regression was used to examine the second research 
question.  The total sample was split to include only those with diabetes in the regression 
analysis.  Variables excluded from the analysis include age, sex and ethnicity as these are 
non-modifiable host characteristics.  Also eliminated were exposures such as having a 
feeding tube, having had gastric surgery.  The health-status variable FIM score was also 
excluded, as deficits in functional status are justification for admission to an AR facility.   
Variables retained for inclusion were antibiotic, and PPI exposure, BMI as a potential 
indicator of nutritional status, CIRS as this instrument included host behaviors related to 
alcohol, substance and tobacco abuse in scoring criteria.  Variables specific to the 
diabetic population, diabetic severity index and diabetic medications were included as 
these are reflective of disease management and monitoring. 
Backward hierarchal logistic regression was conducted assess for potential 
confounders.  Because no primary exposure was identified, and evidence of potential 
confounding present, all variables were inputted into the final model for analysis.  Null 
hypothesis testing was also set at the 5% probability level (p-value ≤ 0.05), two-tailed 
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and estimates of population parameters had a 5% margin of error, and reported as 95% 
confidence intervals. 
Threats to Validity 
External Threats 
Potential threats to validity included both external and internal sources (Frankfort-
Nachmias & Nachmias, 2008).  External sources of bias include unknown differences 
between cases and the controls.  Such differences can limit the generalizability of 
findings to other population groups beyond the study sample.  Unrecognized threats 
impacting external validity can lead to incorrect conclusions and inferences from the 
sample data to different population groups, settings, or temporal situations (Creswell, 
2008).  For this study, potential threats limiting the generalizability of the results include 
selection bias due to the type and location of the healthcare facility, and the study period 
(Creswell, 2008; Burns & Grove, 2005).  Efforts to minimize these potential threats 
included avoiding inferences beyond those groups included in the sample and within the 
specific healthcare setting.  For example, extending claims beyond the AR hospital 
setting.  Also, endemic strains of C. difficile or the emergence of new strains may limit 
generalizations to other geographic regions or time frames. 
Internal Threats 
Internal validity describes the exclusion of rival explanations for the identified 
association between variables (Frankfort-Nachmias & Nachmias, 2008).  Factors that 
pose a threat to the internal validity of this study come from errors introduced during the 
study design, conduct, or analysis process (Rothman, Greenland, & Lash, 2008).  Specific 
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internal validity threats include uncontrollable differences between the cases and controls 
during the sample selection process.  Measures used to reduce this risk included drawing 
the control group from the same population as cases during the same time frame.  Other 
threats include historical events occurring during the study period (Frankfort-Nachmias & 
Nachmias, 2008) such as changes in C. difficile testing methods, or testing 
recommendations, which can impact the effect of the relationship between variables.  
Additionally, the presence of confounding variables can distort the association between 
diabetes, the independent variable, on the outcome of interest.  Unknown or extraneous 
variables not captured in the analysis dataset could have a confounding effect, leading to 
over or underestimation of the effect size (Rothman, Greenland & Lash, 2008).  
Information bias is another internal validity threat resulting from the misclassification of 
exposure or diagnosis (Rothman, Greenland, and Lash, 2008; Szklo & Nieto, 2014).  The 
use of secondary data can increase this threat due to unknown errors in documentation, 
administrative coding, or missing information.  
Additional threats to validity include drawing inaccurate conclusions about the 
data (Creswell, 2009).  Threats associated with statistical validity include inadequate 
sample size, where the available sample size, does not provide adequate power to detect 
an effect, increasing the risk of a type 2 error (Ellis, 2010).  Calculating the study power a 
priori can mitigate this risk by adjusting other associated parameters such as increasing 
the sample size or the effect size.  Imprecise variable definitions and measures can also 
pose a validity threat (Creswell, 2008).  Careful consideration and documentation of 
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variables, including variable definitions, scales of measurement, and appropriate selection 
of statistical tests reduce the risk of erroneous conclusions. 
Ethical Procedures 
Protecting the anonymity and confidentiality of personal health information was 
of paramount concern in this case-control study.  Ethical considerations specific to this 
research study included the type of personal health information collected and the 
safeguarding of sensitive health information during the data collection process.  These 
concerns included determining how best to protect the privacy and dignity of discharged 
patients (Frankfort-Nachmias-Nachmias, 2008; Santelli, 2013).  Formal approval to 
conduct this research study was granted by the Walden University IRB (Approval 
number 04-25-17-0379668).  The IRB application included a signed Data Use Agreement 
from the research site authorizing the collection and analysis of their data.  
This study utilized archival data located in the hospital medical record.  Risk of 
patient harm associated with the collection of data for this study was minimal.  This risk 
assessment was based on the retrospective nature of the study, with data originally 
collected during routine patient care.  No intervention or contact with patients or clinical 
personal was required for data collection.  In addition, no patient identifying information, 
such as patient name, date of birth, social security number, medical record number, or 
residence data was included in the final dataset.  Regardless of the risk, protecting the 
privacy rights and respect for the patient were recognized, and measures aimed at 
preserving the anonymity and confidentiality of the individual’s health information 
implemented (Frankfort-Nachmias & Nachmias, 2008).  Methods employed to protect the 
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privacy of patient information located within the medical record included exclusion from 
the dataset any data that could potentially identify patients and the collection of de-
identified data only.  De-identification includes the removal of any personal and 
geographical information possibly resulting in disclosure of the patient’s identity and 
includes administrative data such as hospital episode numbers.  Other measures to protect 
patients included reducing the risk of data linking by separating the initial list of 
discharged patients which contained hospital episode numbers and the final dataset.  
Limiting the collection of information to only that necessary to answer the research 
question and aggregating the data for analysis also increased adherence to the ethical use 
of health information. 
Professional and ethical conduct across all aspects of the research process is 
essential to protect the privacy of patients and the organizations in which research is 
conducted.  Ethical behavior is a direct concern when research is done in one’s 
professional workplace.  Conducting research in such settings can introduce issues related 
to bias, perceived coercion, and breaches of confidentiality.  Measures to limit these risks 
in this study included the use of a secondary data source, and maintaining a clear 
separation of clinical/professional and investigator roles.  Separation of roles included 
collecting data outside of scheduled work hours.  To avoid potential and actual breaches 
of confidentiality, all chart review was conducted in a private area and limited to only 
those sections of the record relevant to the variables of interest. 
Protecting confidential data and maintaining its integrity requires measures to 
securely manage and store the collected data both electronically and in hard copy.  The 
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dataset is stored electronically on a password-protected portable hard drive.  A single 
backup copy of the dataset is stored in a locked cabinet.  Both the hard drive and backup 
storage devices will be maintained for at least five years as required by Walden 
University.  The dataset does not contain identifying information.  Each study record was 
assigned a unique identifier code.  Once the dataset was completed, the master list which 
included hospital encounter numbers was destroyed.  The use of a master list containing 
the encounter number was necessary to generate the list of discharged patients and to 
locate the medical charts of the sample for manual review.  This master list was critical as 
the research site did not have an electronic medical record, instead, the facility used a 
paper documentation system.  Following patient discharge, the medical record is 
electronically scanned for archival storage.  During active data collection, the master list 
provided the only linkage to the dataset, with access limited to the researcher. 
Summary 
A case-control study design was selected to evaluate an association between 
diabetes and CDI among AR patients.  In this study, the dependent variable is CDI and 
the independent variable, diabetes.  The data analysis plan was based on a fixed number 
of available cases, with two controls identified for each case.  Although the selection of 
cases was drawn from all available CDI discharges during the study period, the controls 
were randomly selected from non-CDI discharges within the same time-period.  The 
medical record of discharged patients meeting the inclusion criteria provided the 
secondary data for the study.  Data collection activities included a review of the medical 
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record and subsequent extraction of select information necessary to measure the 
variables, and construction of a de-identified dataset. 
The use of a case-control design poses a risk for selection and information bias.  
Both forms of bias can threaten the internal validity of the study.  Efforts to minimize 
selection bias included the random sampling of controls, and selecting controls from the 
same population that produced the CDI cases.  Use of a standardized data collection tool 
and a documented process for addressing missing data also helped control for information 
bias.  Another potential risk to validity is the effect of confounding variables.  Use of 
multivariate logistic regression allowed for controlling of covariates within the analysis, 
as a means of addressing the threat of confounding variables. 
This third chapter describes the data analysis plan used to answer each one of the 
research questions and test the study hypothesis.  This plan included a description of the 
study sample and the statistics used to compare cases and controls.  Bivariate and 
multivariate logistic regression models were used to evaluate the relationship between 
diabetes and CDI and to identify modifiable risk factors.  Charts, tables, and narrative are 
used to summarize the results of this study. 
Ethical considerations are a critical element of any research study.  For this 
dissertation research, permission was granted by Walden University IRB.  In addition, 
authorization to access the medical records of discharged patients at the proposed 
research site was given by the facility CEO.  Measures to protect the privacy of patient 
information included the purposeful extraction of data to exclude any patient identifying 
data, the secure storage of the dataset, and the aggregate analysis of data. 
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Chapter 4: Results  
Introduction 
The purpose of this research study was to evaluate the association between 
diabetes and CDI.  Specifically, to assess if there is a relationship between diabetes and 
CDI among hospitalized patients in the acute rehabilitation (AR) setting and if are there 
any modifiable environmental and host characteristics associated with CDI among 
hospitalized diabetics in this select setting.  This chapter describes the sample population, 
and present results of the multiple logistic regression analysis used to answer the 
aforementioned research questions. 
Results 
Sample Characteristics 
Participants age ranged from 21 to 97 years with a negatively skewed distribution 
(Figure 3.).  BMI values fell between 13.7 to 59.9, with positive skew and leptokurtic 
distribution (Figure 4.).  Both CIRS and FIM showed normal distribution.  Among those 
with diabetes, the DCSI score ranged from 0 with no complications to a score of 13; 
distribution had a positive skew and negative kurtosis.  The majority of those with 
diabetes managed their disease with insulin (16%) or a combination of oral and insulin 





















The sample available for analysis was predominately female (51.8%) with a mean 
age of 68 years (Table 3).  Across both cases and controls, most participants were 
Caucasian (59.4%), Hispanic/ Latino (28.3%), Native Americans (9.5%).   
Black/African Americans (1.9%) and Asian (0.8%) were in the minority.  The most  
frequent diagnosis among patients admitted to the AR facility was orthopedic conditions 
(28.3%), followed by stroke and debilitation, with each accounting for 17% of the 
sample.  Those categorized as other (10.6%) included patients admitted with arthritis, 
cardiac or pain syndrome diagnoses.  Among those with CDI, debilitation was the most 










Figure 4.  Distribution and frequency of sample 
BMI. 
 




Table 3  
Characteristics of Sample Population by Outcome Variable 
Characteristics Total  
Sample 
(N = 473) 
Cases 
(n = 102) 
Controls 
(n = 371) 
p-value (95% CI) 
Age, years, mean (SD) 
Sex (%) 
   Female 
   Male 
Race/ Ethnicity (%) 
   Caucasian 
   Hispanic 
   African American 
   Asian 
   AI/AN 
BMI, mean (SD) 
Diabetes, yes (%) 
Admit Diagnosis (%) 
   Stroke 
   Spinal Cord  
   Multiple Trauma 
   Brain Dysfunction 
   Amputation 
   Burns 
   LE Fracture 
   Orthopedic Cond. 
   Neurological 
   Debilitation 
   Other 
Prior Location (%) 
   Acute Care 
   Home 
   Long-term Acute 
   Nursing Home 



























































































   .931 (-2.99, 3.26) 
   .219 
 
 






   .136(-.36, 2.61) 
   .107 

















<.001* (-3.47, -1.30) 
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Characteristics Total  
Sample 
(N = 473) 
Cases 
(n = 102) 
Controls 
(n = 371) 
p-value (95% CI) 
DCSI, mean (SD) † 
FIM, mean (SD) 
Antibiotics, yes (%) 
PPI, yes (%) 
Tube Feeding, yes (%) 
GI Surgery, yes (%) 
Diabetes Therapy (%)† 
   Diet 
   Insulin 
   Oral 
   Oral & Insulin 
    
3.64 (3.17) 


































   .621 (-.136, .811) 
   .002* (2.75, 12.26) 
<.001* 
<.001* 
   .013* 
   .003* 
   .047* 
  
 Note.  *Statistically significant at p-value ≤ 0.05, two-tail; CI = confidence interval  
† Variable includes only those with a diagnosis of diabetes at time of admission to AR facility. 




Differences between groups were tested using the independent t-test for 
continuous variables and Fisher’s exact test for categorical variables.  Ninety percent (p-
value < 0.001) of patients transferred from acute care settings, and seven percent from 
long-term acute care facilities (LTAC).  Comparisons between acute care and other 
healthcare settings for CDI frequency, found statistically significant differences between 
both LTAC (X2 (1) = 15.59, p = <0.001) and nursing home settings (X2 (1) = 6.21, p = 
0.03) as prior locations.  Notable differences (p-value ≤ 0.05) were also found among 
variables related to exposure and health status.  Comparison of means between cases and 
controls found differences between CIRS and FIM scores with CDI cases having a higher 
average CIRS score (m = 19.83) compared to those who were not diagnosed with CDI (m 
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= 17.46).  Patients with CDI (n = 102) were found to have lower mean FIM scores (m = 
76.73) indicating less functional independence, compared to the control group (m = 
84.23).  Fisher’s exact test was used to evaluate differences in categorical variables 
between cases and controls, with differences (p-value <0.05) noted for prior exposure to 
antibiotics, protein pump inhibitors (PPI), the presence of a feeding tube, GI surgery 
within 30 days of admission, admission diagnosis, and prior location.  Similar 
frequencies between the two groups were found among host characteristics of age, 
gender, and ethnicity.  No statistically significant differences were also noted among the 
health status variables body mass index (BMI), and diagnosis of diabetes.  
For continuous variables, all interactions tested were found non-significant (p-
value > 0.05) indicating that the assumption for linearity was met.  Assessment of 
collinearity found tolerance values less than 0.1 and variance inflation factor (VIF) less 
than 10, suggesting no violation of this assumption.  An interaction between age and 
diabetes, with differences in effect size, was found to exist between those aged 65 and 
younger and those older than 65 years (Table 4).   
 
Table 4  
Observation of Age as an Effect Modifier 
 
Variable 
≤ 65 Yrs. >65 Yrs. 
OR p-value 95% CI OR p-value 95% CI 
Diabetes 2.20 .032 1.07, 4.52 1.12 .708 .631, 1.97 
  





Research Question 1 and Hypothesis 
Research Question: Is there any relationship between diabetes and CDI among 
hospitalized patients in the acute rehabilitation (AR) setting? 
Ho1: There is no relationship between diabetes disease and CDI among patients in 
the AR setting.  
H11: There is a significant relationship between diabetes and CDI among patients 
in the AR setting. 
Thirty-six percent of the sample was admitted to the AR hospital with a diagnosis 
of diabetes.  Results of the Pearson's chi-square test found no association (X2 (1) = 2.66, p 
= 0.10) between diabetes and CDI.  The crude odds ratio (OR = 1.45), as a measure of 
effect, suggested those with diabetes were 45% more likely to develop CDI than non-
diabetics.  However, this finding was not statistically significant (p = 0.10; 95% CI [0.93, 
2.26]).  Evaluation for the presence of effect modifiers influencing the relationship 
between diabetes and covariates found age to modify the relationship between diabetes 
and CDI, evidenced by increasing both the odds ratio and the statistical significance of 
the association (table 4).  
 To determine the effect of potential confounding on the relationship multivariate 
logistic regression modeling was conducted.   Variables selected for inclusion were those 
identified from bivariate logistic regression to have a statistically significant (p-value ≤ 
0.05) association with CDI, and those considered relevant risk factors were included: age, 
gender, ethnicity, BM, CIRS, FIM, admission diagnosis group, prior location, antibiotics, 
PPI, feeding tube, GI surgery, and age x diabetes interaction (Table 5). 
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Table 5  


















Diabetes 1.075 .473 6.047 1 .014* 2.930 1.244 6.902 
Age >65  .409 .348 1.380 1 .240 1.505 .761 2.976 
Male  .776 2.53 1.189 1 .275 1.318 .802 1.166 
Caucasian  .452 .266 2.878 1 .090 1.571 .932 2.648 
BMI >25 -.571 .257 4.034 1 .045* .596 .360 .988 
CIRS  .018 .029 .37 1 1 .542 1.018 .962 1.077 
FIM -.015 .006 5.543 1 .019* .986 .974 .998 
Admit Group: Debility   .383 .330 1.348 1 .246 1.467 .768 2.802 
Acute Care Loc:   .858 .398 4.645 1 .031* 2.358 1.081 5.143 
Antibiotic  .987 .306 10.44
4 
1 .001* 2.684 1.475 4.886 
PPI  .416 .255 2.655 1 .103 1.515 .919 2.498 
Feeding Tube  .273 .425 .413 1 .521 1.314 .571 .3024 
GI Surgery 1.664 .687 5.869 1 .015* 5.280 1.374 20.293 
AGE*Diabetes -.930 .521 3.191 1 .174 .394 .142 1.095 
Constant -1.739 .849 4.196 1 .041 .176   
  
 Note.  Statistically significant t at p-value ≤ 0.05, two-tail; CI = confidence interval  
 
 
 A hierarchical backward elimination modelling assessment found the variables 
gender and having a feeding tube to have negligible effect as potential confounders and 
were removed from the final model.  Although, the CIRS variable had the least 
significance, having this variable in the model provided a narrower confidence interval 
and was retained in the final model (Table 6).  In the final model, having had GI surgery 
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in the 30 days before admission was excluded due to the imprecise confidence interval, 
95% CI [1.37, 20.29], likely resulting from the small number of patients.  
 
Table 6   

























Diabetes   .929 .428 4.703 1   .030* 2.531 1.093 5.858 
Age: >65   .327 .340   .924 1   .366 1.387   .712 2.700 
Caucasian   .389 .261 2.214 1   .137 1.475   .884 2.461 
BMI:  ≥ 25 -.494 .252 3.841 1   .050*   .610   .373 1.000 
CIRC   .031 .028 1.268 1   .260 1.032   .977 1.090 
FIM -.015 .006 6.570 1   .010*   .985   .973   .996 
Acute Care Loc.   .799 .383 4.351 1   .037* 2.223 1.049 4.709 
Admit Group: Debility 
 
  .420 .322 1.696 1   .193 1.522   .809 2.863 
Antibiotic  1.046 .299 12.207 1 <.001* 2.846 1.583 5.116 
PPI   .493 .250 3.879 1   .049* 1.637 1.002 2.672 
MD*Age -.855 .513 2.776 1   .096   .425   .155 1.163 
Constant -2.099 .832 6.369 1   .012   .123   
 
Note.  Nagelkerke R Square =.181.  * statistical significance p-value ≤ 0.05, two-tail; CI = confidence 
interval  
  
 After controlling for potential confounders, the sample of acute rehabilitation 
patients with diabetes had 2.53 greater odds of developing CDI compared to those 
without diabetes (p = 0.03, 95% CI [1.09, 5.86]).  Including the variable GI surgery in the 
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past 30 days prior to admission increased the odds ratio but reduced estimate precision 
(OR = 2.8, Wald = 5.689, p = 0.017, 95% CI [1.20, 6.61]).  Based on these findings, the 
null hypothesis that there is no association between diabetes and CDI was rejected in 
favor of the alternate hypothesis that there is an association between diabetes and CDI 
after controlling for race, BMI, CIRC, FIM, coming from an acute care location, debility 
admitting diagnosis group, and exposure to antibiotic and PPI medications.  
Research Question 2 and Hypothesis 
Research Question 2: Are modifiable environmental (antimicrobial and 
medication exposures) and host characteristics (behaviors, BMI, diabetes management) 
associated with CDI among hospitalized diabetics in AR settings? 
Ho2:  There is no relationship between selected modifiable variables and CDI 
among diabetic patients in the AR setting. 
H12:  There is a relationship between modifiable variables and CDI among 
diabetic patients in the AR setting. 
Descriptive statistics to explore differences between those with diabetes and non-
diabetics are presented in Table 7.  Several statistically significant differences were noted 
with a higher percentage of Native Americans (15.9% vs. 5.7%, p = 0.003) having a 
diagnosis of diabetes.  Differences were also noted amongst Hispanics who also had a 
higher proportion of diabetes (34.1% vs. 24.9%, p = 0.032) and Caucasians who had 
higher numbers of non-diabetics (67.7% vs. 45.5%, p < 0.001).  No differences were 
found for African Americans or Asian ethnicities.  Differences between groups were also 
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found for BMI, admission diagnosis, CIRS.  No differences were found between groups 
for antibiotic or PPI exposure, FIM score, prior location, feeding up or GI surgery.  
 
Table 7  
Characteristics of Sample by Exploratory Independent Variable 
Characteristics Total  
Sample 




(n = 297) 
p-value (95% CI) 
Age, years, mean (SD) 
Sex (%)ǂ 
   Female 
   Male 
Race Ethnicity (%) 
   Caucasian 
   Hispanic 
   Black/AA 
   Asian 
   AI/AN 
BMI, mean (SD) 
CDI, yes (%)ǂ 
Admit Diagnosis (%) 
    Stroke 
    Spinal Cord  
    Multiple Trauma 
    Brain Dysfunction 
    Amputation 
    Burns 
    LE Fracture 
   Orthopedic Cond. 
   Neurological 
   Debilitation 
   Other 












































































  .833 (-2.94, 2.37) 









<.001 (-4.71, -2.24) * 
















Characteristics Total  
Sample 




(n = 297) 
p-value (95% CI) 
   Acute Care 
   Home 
   Long-term Acute 
   Nursing Home 
CIRS, mean (SD)ǂ 
DCSI, mean (SD) † 
FIM, mean (SD) 
Antibiotics, yes (%)ǂ 
PPI, yes (%)ǂ 
Tube Feeding, yes (%)ǂ 
GI Surgery, yes (%)ǂ 
Diabetes Therapy (%)† 
   Diet 
   Insulin 
   Oral 















































<.001 (-4.21, -2.34) * 
 
  .977 (-4.15, 4.03) 
  .087 
  .502 
  .166 
1.00 
  
Note: *Statistical significant at p-value ≤ 0.05, two-tail; CI = confidence interval  
† Variable includes only those with a diagnosis of diabetes at time of admission to AR facility. 
 ǂ Fishers Exact test 
 
 The final model (Table 8), indicate those with diabetes, when exposed to 
antibiotics have 4.2 times greater odds of acquiring CDI compared to those who did not 
receive antimicrobial therapy (OR = 4.24, p = 0.005).  For patients receiving insulin the 
odds of diabetes were 2.6 (p = 0.015).  Exposure to PPI medication increased the odds of 
CDI compared to diabetic patients who did not receive PPI.  CIRS appeared to have a 
confounding effect on PPI exposure (Table 9).  Overweight and obese persons had a 
lower risk of CDI compared to normal and underweight with each unit decrease in BMI 
the odds of CDI were reduced by 0.43.  However, neither the relationship between PPI 
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and CDI or between BMI and CDI were statistically significant.  Diabetes severity, 
measured using the Diabetes Complication Index Score was also not a significant risk 
factor, although less severe disease did lower the odds of CDI.  However, a wide 
confidence interval was noted across all these variables.  The analysis found antibiotic 
exposure (OR = 3.86, p = 0.010) and insulin therapy (OR = 2.56, p = 0.015) as modifiable 
risk factors for CDI.  Therefore, the null hypothesis that there are no modifying factors in 
this population was rejected in favor of the alternate hypothesis that modifying factors are 
present among diabetic AR patients after controlling for BMI, DCIS, CIRS, and PPI. 
 
Table 8  
Multiple Logistic Regression Examining Modifiable Risk Factor Among Diabetics 
       
95% CI 
Risk Factor B SE Wald df  p-value Exp(B) Lower  Upper 
Antibiotic 
PPI 






  .612 
 -.561 














  .678 
5.961 


















  .570 
1.038 
 2.563 
  .960 
 .046 
1.376 
  .842 
  .258 
  .950 
 1.204 
  .843 
 
10.869 
  4.041 
  1.262 
  1.135 
  5.456 
  1.093 
  
 Note.  Hosmer and Lemeshow Test: X2 (8) = 7.524 (p-value = 0.481); Nagelkerke R square = 
.174; * statistically significant at p-value ≤ 0.05, two-tail; CI = confidence interval. 





Table 9   
Observed Effect of CIRC on Logistic Regression Model Examining Modifiable Risk 
Factor Among Diabetics 
 Adjusted Model with CIRS Adjusted Model without CIRS 
   95% CI   95%CI 
Risk Factors OR p-value Lower Upper OR p-value Lower Upper 
Antibiotics 3.867 .010 1.376 10.869 3.748 .012 1.342 10.469 
PPI 1.844 .126   .842  4.041 2.076 .051   .997  4.325 
BMI >25   .570 .166   .258  1.262   .553 .141   .251  1.218 
Insulin 2.563 .015 1.204  5.456   .382 .012   .180    .830 
DCSI   .960 .540   .843  1.093   .382 .730   .867  1.105 
CIRS 1.038 .410   .950  1.135 3.748 .012   
Constant   .046 .003    .234 .036   
 
Note.  Adjusted model without CIRS: Hosmer and Lemeshow Test: X2 (8) = 3.83 (p = 0.871); Nagelkerke R 




The purpose of this study was to examine the relationship between diabetes and 
CDI and to identify any modifiable risk factors associated with CDI in the acute inpatient 
rehabilitation setting.  This chapter presented the results of the data analysis conducted to 
address the two research questions related to above-noted purpose.  Of the initial 7593 
records identified during the study period, a total of 473 records met the inclusion criteria 
for analysis.  Comparisons between cases and controls found differences related to 
admission diagnosis with cases having a higher frequency of amputation and debility, and 
having come from a post-acute setting.  The control group had a higher frequency of 
antibiotic exposure.  Among those with a diagnosis of diabetics, a higher percentage of 
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cases were prescribed insulin to manage their disease compared to oral or combination 
regimes.  Hierarchical multivariate logistic regression conducted to evaluate the 
relationship between diabetes and CDI, suggested that diabetes is associated with CDI 
after controlling for potential confounding variables in this population.  Age was 
identified as an effect modifier in the relationship.  Results from this analysis should be 
interpreted with caution due to the small number of cases, the small effect size, and 
presence of interacting variables.  
Findings from the analysis examining modifiable risk factors among this acute 
rehabilitation population with diabetes found only exposure to antibiotics and insulin to 
have an association with CDI of statistical significance.  Interpretation of these findings, 
including both significant and non-significant results, implications for positive social 





Chapter 5: Discussion, Conclusions, and Recommendations 
Introduction 
 Clostridium difficile is a leading cause of healthcare associated infection in the 
United States (Magill et al., 2014) and is associated with a significant health and 
economic burden (Desai et al., 2016; McGlone et al., 2012).  Diabetes is a highly 
prevalent disease associated with increased healthcare utilization from disease-related 
complications (Zhuo et al., 2014).  The purpose of this research was to evaluate the 
association between diabetes and the risk for CDI and to identify any modifiable risk 
factors specific to patients with diabetes.  The study used an ecosocial theory of disease 
distribution as the theoretical framework.  The knowledge gained from this research will 
increase the understanding of CDI in select healthcare populations and settings.   
 Our case-control study examined the relationship between diabetes and CDI 
among patients discharged from an acute medical rehabilitation facility.  Multiple logistic 
regression was used to test for the association between the dependent variable CDI and 
the exposure variable, diabetes.  Results indicated a statistically significant association 
between diabetes and increased odds for CDI. The study also sought to identify the 
presence of modifiable risk factors for CDI among diabetic patients in this healthcare 
setting.  The results found antibiotic exposure and insulin therapy associated with an 
increased odds ratio for CDI in this population sample. 
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Interpretation of Findings 
Research Question 1 
Results of the analysis testing the association between diabetes and CDI found 
patients with diabetes had increased odds of developing CDI after controlling for 
confounding variables.  Identifying an association between diabetes and CDI in this 
sample population supports previous research examining alterations and differences in 
the intestinal flora of persons with diabetes (Karlsson et al., 2013; Larsen et al., 2010; 
Qin et al, 2012a).  Such differences are permissive with intestinal microbiota diversity 
shown among population groups attributed to variation in diet, genetic characteristics, 
exposures and disease states (Escobar et al., 2014).  Admissions to healthcare settings, 
altered nutritional status, and medications have also been cited as impacting the intestinal 
biome (Buonomo & Petri, 2016).  These factors and cumulative exposures among 
persons with diabetes may explain the increased odds for CDI and support previous 
studies suggesting susceptibility to CDI is increased among those with diabetes (Shakov 
et al., 2011; Tartof et al., 2014; Wenisch et al, 2012). 
Exposure to antibiotic therapy in the previous 30 days at time of admission had 
the strongest relationship for with CDI (OR 2.8, p = <0.001, 95% CI [1.6, 5.1]).  A result 
concurring with findings reported in the literature suggesting disruption to the intestinal 
microbiota leads to expansion of C. difficile bacteria (Becattini, Taur, & Pamer, 2016; 
Theriot et al., 2014).  In my study, differences in the frequency of antibiotic exposure 
were noted in the diabetic population.  Antibiotic exposures were more common among 
those with CDI.  However, when comparing persons with diabetes to non-diabetics 
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(Table 7) no difference in exposure was found.  Frequently of exposure to antibiotics may 
be related to disease states.  Patients admitted to the AR setting from acute care facilities 
may have greater exposure to antibiotic therapy based on their state of health, medical 
intervention, and standard antibiotic utilization.  Admission to the AR hospital setting 
from acute care and LTAC locations was found to increase the odds of CDI in this 
sample.  This differs from opposite findings in the acute care literature where admission 
from long-term care or nursing homes is considered a risk factor (Durham et al., 2016).  
Possible explanations for the discrepancy in my study may indicate that a prior exposure 
to any healthcare setting, acute or long-term, may increase the risk for CDI, or that the 
duration of exposure to other healthcare settings, including the facilities underlying 
burden of CDI increases the risk of infection.   
Antibiotic exposure could be related to the admission diagnosis, with a greater 
proportion of non-diabetic patients admitted following orthopedic surgery in which a 
single prophylactic dose of antibiotics is routinely given as part of surgical site 
prevention (Berríos-Torres et al., 2017; Bratzler et al., 2013).  Also, patients with 
diabetes may have experienced longer duration or cumulative exposure to antibiotics with 
debilitation, the most frequent reason for admission.  
Study participants older than 65 years of age were found to have an increased risk 
for CDI, however this finding was not statistically significant.  Although, age did not 
have a confounding effect on the relationship between diabetes and CDI, the variable was 
an effect modifier of this relationship.  Previous studies have found higher incidence of 
CDI among those of older age (Lessa, 2015; Pechal, Lin, Allen, & Reveles,2016).  Non-
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significant findings in this study may reflect the differences in patients admitted to the 
AR setting compared to acute care facilities or other geographical locations. 
Research Question 2 
The second research question examined modifiable risk factors associated with 
CDI among diabetics only.  In this sub-sample of patients with diabetes, recent exposure 
to antibiotics (within prior 30 days) and glucose control medication (insulin therapy) 
were found associated with an increased risk for CDI.  Exposure to antibiotics increased 
the odds of CDI by more than three-fold.  Although there was no significant difference in 
the frequency of antibiotic exposure between diabetics and non-diabetics in this study, 
studies examining antibiotic utilization indicate that those with diabetes are more likely to 
receive broad spectrum antibiotics (Jenkins et al., 2014; Jääskeläinen, Hagberg, Forsblom 
& Järvinen, 2017) and for a longer duration of time (Jääskeläinen et al., 2017).  More 
aggressive treatment of infection and prophylaxis use in surgical patients is likely based 
on previous studies linking diabetes disease to an increased risk of infection and infection 
related mortality (Martin et al., 2016; Magliano et al., 2015).  However, such prescribing 
practices can lead to unnecessary exposure to antibiotics and increased risk for CDI 
(Stevens, 2011).  Thus, efforts to reduce exposure including antibiotic selection, and 
minimal duration of therapy have strong potential in CDI prevention activities.  
 Among those on medications for glucose control, insulin therapy was associated 
with an increased risk for CDI.  Recent studies have also found insulin to increase the 
risk of infection in hospitalized patients with diabetes, while oral antiglycemics have 
been found to lower the risk for CDI (Eliakim-Raz et al., 2014).  The protective quality of 
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oral antiglycemics, has been linked to increased microbial diversity within the gut.   Oral 
antiglycemics increase butyrate-producing organisms (Antharam et al., 2013; Zhang et 
al., 2017), which in turn is thought to limit available energy sources for C. difficile 
expansion.  However, the overall role of oral therapies and insulin is likely confounded 
by factors such as therapeutic dosing, combination therapies, and the role of long-acting 
insulins and glucose control.  It is worth considering the impact of increased monitoring 
and tighter control of blood glucose levels in hospitalized patients.  In addition, insulin is 
recommended over other antihyperglycemic agents in hospitalized patients for blood 
glucose management (ADA, 2016), which may account for the higher insulin utilization.  
The CIRS index includes elements of diabetes control within the score allocation, using 
hemoglobin A1c results.  The CIRS index provided a measure of comorbidity and 
included measures of behavior such as tobacco, alcohol, or other dependent behaviors.  
CIRS index was found to be significantly higher when compared to non-diabetic patients.  
However, this variable was not found to offer significant value to the model.  Early 
evaluation of patients for resuming home regimes or appropriateness of 
antihyperglycemic agent could reduce insulin exposure and limit risk for CDI. 
Limitations of the Study 
This study is subject to several limitations including the use of a case-control 
design.  Inherent limitations within the case-control design increase the potential for bias.  
Informational bias could result from differences in the quality of information within the 
medical record and misdiagnosis.  Efforts to mitigate this risk included the use of a 
standardized collection tool and confirmatory review of test results for inclusion as a 
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case.  Laboratory conformation of C. difficile toxin did eliminate a sizeable proportion of 
cases (53%) originally identified using the ICD-10 codes.  It is also possible that not all 
cases of CDI occurred during the AR admission.  Marjolein and colleagues (2012) 
reported the highest risk for CDI occurring within the 30 days following antibiotic 
exposure.  Thus, cases of CDI occurring after discharge from the AR hospital but within 
the 30-day window were not captured for analysis. 
Adherence to the inclusion criteria also impacted the final sample size available 
for analysis and the ability to generate adequate power to confidently accept observed 
differences between groups.  There was also the possibility of underrepresentation of 
cases if patients experienced onset of symptoms post discharge.   This study focused on a 
specific healthcare population.  Therefore, findings from this study may not transfer to 
other healthcare settings.  In addition, characteristics of the sample may reflect unique 
characteristics of the geographical location and patient population within the U. S., 
particularly characteristics related to age and ethnicity.   The inability to control for all 
possible risk factors also limits the interpretation of the findings.  Although, patient 
comorbidities were measured and included as covariates, the use of index scores 
prevented further drill down into specific behaviors or conditions, and a consideration for 
future studies  
Recommendations 
Recommendations for future research include expanding study populations to 
other geographical locations and healthcare settings.  Using a broader population offers 
the potential to obtain larger samples and to compare findings between different 
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healthcare settings.  Other recommendations based on the methodology of the current 
study and theoretical framework is the further exploration of the multiple pathways 
related to both susceptibility and resistance to CDI among patients with diabetes. 
Pathways related to social economic status and environmental exposures, as well as a 
more detailed approach in controlling for comorbidities and health-related behaviors. 
Implications for Positive Social Change 
There are several implications for positive social change because this study 
focuses on a topic important for local and national efforts in HAI prevention.  The high 
morbidity and mortality associated with healthcare-associated CDI have led to prevention 
efforts becoming a public health priority at the national level (Centers for Disease 
Control and Prevention, 2013; Office of Disease Prevention and Health Promotion, 
2016).  Findings from this research have the potential to identify select population groups 
at risk CDI, and more importantly to identify modifiable risk factors for CDI.  
Understanding associations between at-risk populations, such as those with diabetes, and 
CDI expand what is currently known about this infection and may offer insights and 
opportunities for clinicians and researchers to develop targeted prevention strategies and 
interventions.  Findings from this research have the potential improve health outcomes 
among those with diabetes in the post-acute healthcare settings by improving the quality 
and safety of healthcare delivery.  Insights from this research could also impact health 
outcomes of diabetics by improving the quality and safety of healthcare delivery, through 
reinforcing the role of antibiotic stewardship programs and appropriate prescribing 
practices by clinicians in post-acute settings.  Addressing the burden of CDI through 
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effective prevention efforts also has economic implications for reducing healthcare costs, 
both direct and indirect for the individual and healthcare facilities.  In addition, 
improving health outcomes among those with diabetes disease also offers economic 
benefits for all levels of society. 
Conclusion 
Healthcare associated infections place a considerable burden on individuals, 
healthcare systems and society as a whole.  HAI reduction is increasingly becoming a 
measure of quality care and linked to national healthcare policy.  CDI has been identified 
as a leading cause of HAI and associated with increased morbidity and mortality.  Efforts 
to understand the mechanisms contributing to CDI suggest disruptions to the intestinal 
microbiome have a key role.  Increasingly research on the intestinal microbiome indicates 
a number of pathways or exposures over time create unique ecosystems.  Differences 
have also been found among those with diabetes when compared to non-diabetics.  Yet 
little research has been conducted to address CDI in the diabetic population.  There is 
also limited research regarding CDI in the AR setting. 
To my knowledge, this is the first study to examine the relationship between 
diabetes and CDI in the AR hospital setting.  Findings from this study showed that those 
with diabetes in an AR hospital were more likely to develop CDI compared to non-
diabetics.  Risk factors sensitive to intervention were found for antibiotic and insulin 
exposure.  The role of antibiotics as a risk factor reinforces the need for judicious use of 
antibiotics across the healthcare spectrum.  The role of insulin as a risk factor remains 
unclear; however increased awareness among clinicians of the potential risk supports a 
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proactive approach to diabetes management in the AR setting.  Additional research is 
needed to further our understanding of the relationship between diabetes and CDI and the 
factors which increase CDI susceptibility and resilience.  This study advances what is 
currently known regarding the relationship between diabetes and CDI and moves us 




Abdelsattar, Z. M., Krapohl, G., Alrahmani, L., Banerjee, M., Krell, R. W., Wong, S. L., 
… Hendren, S. (2015). Postoperative burden of hospital-acquired Clostridium 
difficile infection. Infection Control and Hospital Epidemiology, 36(1), 40–6. 
doi:10.1017/ice.2014.8 
Alford, S. (2014). A predictive model for dementia risk in elderly adults with prediabetes 
[Doctoral dissertation]. Available from ProQuest Dissertations & Theses Global 
database (3669688) 
American Academy of Physical Medicine & Rehabilitation. (2012). Inpatient 
rehabilitation. Retrieved from http://www.aapmr.org/docs/default-
source/protected-advocacy/Position-Statements/inpatient-rehabilitation--
justification-for.pdf?sfvrsn=2 
American Diabetes Association (2014). Diagnosis and classification of diabetes mellitus. 
Diabetes Care, 37(suppl_1), S81–S90.  doi: 10.2337/dc14-S081 
American Diabetes Association (2017). Diabetes care in the hospital. Diabetes Care, 
40(Supplement 1), S120-S127. doi.org/10.2337/dc17-S017 
American Medical Rehabilitation Providers Association (2016). Inpatient hospital-level 
medical rehabilitation improves lives. Retrieved from 
https://www.amrpa.org/AMRPA_Newsroom.aspx?ID=Medical_Rehabilitation_I
mproves_Lives 
Antharam, V. C., Li, E. C., Ishmael, A., Sharma, A., Mai, V., Rand, K. H., & Wang, G. 
P. (2013). Intestinal dysbiosis and depletion of butyrogenic bacteria in 
96 
 
Clostridium difficile infection and nosocomial diarrhea. Journal of Clinical 
Microbiology, 51(9), 2884–2892. doi:10.1128/JCM.00845-13 
Armstrong, D. (2000). Social theorizing about health and illness. In G.L. Albrecht, R. 
Fitzpatrick & S. C. Scrimshaw (Eds.). Handbook of social studies in health and 
medicine (pp. 24-35). London, England: Sage. doi: 10.4135/9781848608412.n3 
Arriola, V., Tischendorf, J., Musuuza, J., Barker, A., Rozelle, J. W., & Safdar, N. (2016). 
Assessing the risk of hospital-acquired Clostridium difficile infection with proton 
pump inhibitor use: A meta-analysis. Infection Control & Hospital Epidemiology, 
37(12). 1408-1417. doi:10.1017/ice.2016.194 
Aschengrau, A., & Seage III, G.R. (2008). Essentials of epidemiology in public health 
(2nd ed.). Sudbury, MA: Jones and Bartlett 
Bakullari, A., Metersky, M. L., Wang, Y., Eldridge, N., Eckenrode, S., Pandolfi, M. M., 
... Moy, E. (2014).  Preventing healthcare-associated infections: Results and 
lessons learned from AHRQ’s HAI program [Supplemental issue].  Infection 
Control and Hospital Epidemiology, 35(S3), 10-16.  doi: 10.1086/677872 
Barletta, J. F., & Sclar, D. A. (2014). Proton pump inhibitors increase the risk for 
hospital-acquired Clostridium difficile infection in critically ill patients. Critical 
Care, 18(6), 714. http://doi.org/10.1186/s13054-014-0714-7 
Barth, H., Aktories, K., Popoff, M R., & Stiles, B. G. (2004). Binary bacterial toxins: 
Biochemistry, biology, and applications of common Clostridium and Bacillus 




Bartlett, J. G. (2008). Historical perspectives on studies of Clostridium difficile and C. 
difficile infection. Clinical Infectious Diseases, 46(S1), S4-S11. doi: 
10.1086/521865 
Bartlett, J. D., Moon, N., Chang, T. W. Taylor, N., & Onderdonk, A. B. (1978). Role of 
Clostridium difficile in antibiotic-associated pseudomembranous colitis. 
Gastroenterology 75(5). 778-782. Retrieved from http://www.gastrojournal.org  
Bauer, M. P., Notermans, D. W., Van Benthem, B. H., Brazier, J. S., Wilcox, M. H., 
Rupnik, M., ... Kuijper, E. J. (2011). Clostridium difficile infection in Europe: a 
hospital-based survey. The Lancet, 377(9759), 63-73. doi: 10.1016/S0140-
6736(10)61266-4 
Bavishi, C., & DuPont, H. L. (2011). Systematic review: The use of proton pump 
inhibitors and increased susceptibility to enteric infection. Alimentary 
Pharmacology and Therapeutics, 34(11–12), 1269–1281. doi: 10.1111/j.1365-
2036.2011.04874.x 
Becattini, S., Taur, Y., & Pamer, E. G. (2016). Antibiotic-induced changes in the 
intestinal microbiota and disease. Trends in Molecular Medicine, 22(6), 458–478. 
doi: 10.1016/j.molmed.2016.04.003 
Bejor, M., Ramella, F. C., Toffola, E. D., Comelli, M., & Chiappedi, M. (2013). Inpatient 
rehabilitation outcome: A matter of diagnosis? Neuropsychiatric Disease and 
Treatment, 9, 253–257. doi: 10.2147/NDT.S39922 
Berríos-Torres, S. I., Umscheid, C. A., Bratzler, D. W., Leas, B., Stone, E. C., Kelz, R. 
R., … Schechter, W. P. (2017). Centers for Disease Control and Prevention 
98 
 
guideline for the prevention of surgical site infection, 2017. JAMA Surgery, 
152(8), 784. doi:10.1001/jamasurg.2017.0904 
Best, C. (2008). Enteral tube feeding and infection control: how safe is our practice? 
British Journal of Nursing, 17(16), 1036-1041. doi: 
10.12968/bjon.2008.17.16.31069 
Bertoni, A. G., Saydah, S., Brancati, F. L (2001). Diabetes and the risk of infection- 
related mortality in the U. S. Diabetes Care, 24(6), 1044-1049. doi: 
10.2337/diacare.24.6.1044 
Biedermann, L., & Rogler, G. (2015). The intestinal microbiota: Its role in health and 
disease. European Journal of Pediatrics, 174(2), 151-167. doi: 10.1007/s00431-
014-2476-2 
Bishara, J., Farah, R., Mograbi, J., Khalaila, W., Abu-Elheja, O., Mahamid, M., & Nseir, 
W. (2013). Obesity as a risk factor for Clostridium difficile infection. Clinical 
Infectious Diseases, 57(4), 489-493. doi: 10.1093/cid/cit280 
Bisung, E., & Elliott, S. J. (2014). Toward a social capital based framework for 
understanding the water-health nexus. Social Science & Medicine, 108, 194-200. 
doi: 10.1016/j.socscimed.2014.01.042 
Bliss, D. Z., Johnson, S., Savik, K., Clabots, C. R., Willard, K., & Gerding, D. N. (1998). 
Acquisition of Clostridium difficile and Clostridium difficile-associated diarrhea 
in hospitalized patients receiving tube feeding. Annals of Internal Medicine, 
129(12), 1012-1019. doi: 10.7326/0003-4819-129-12-199812150-00004 
Booth, G. L., & Hux, J. E. (2003). Relationship between avoidable hospitalizations for 
99 
 
diabetes mellitus and income level. Archives of Internal Medicine, 163(1), 101-
106. doi: 10.1001/archinte.163.1.101 
Bratzler, D. W., Dellinger, E. P., Olsen, K. M., Perl, T. M., Auwaerter, P. G., Bolon, M. 
K., ... & Steinberg, J. P. (2013). Clinical practice guidelines for antimicrobial 
prophylaxis in surgery. Surgical infections, 14(1), 73-156. doi: 
10.1089/sur.2013.9999 
Brestoff, J. R., & Artis, D. (2013). Commensal bacteria at the interface of host 
metabolism and the immune system. Nature Immunology, 14(7), 676–684. 
doi:10.1038/ni.2640 
Britton, R. A., & Young, V. B. (2014). Role of the intestinal microbiota in resistance to 
colonization by Clostridium difficile. Gastroenterology, 146(6), 1547-1553. doi: 
10.1053/j.gastro.2014.01.059 
Brown, E., Talbot, G. H., Axelrod, P., Provencher, M., & Hoegg, C. (1990). Risk factors 
for Clostridium difficile toxin-associated diarrhea. Infection Control & Hospital 
Epidemiology,1(6), 283-290. doi: 10.2307/30145487 
Buendgens, L., Bruensing, J., Matthes, M., Duckers, H., Luedde, T., Trautwein, C., ... 
Koch, A. (2014). Administration of proton pump inhibitors in critically ill medical 
patients is associated with increased risk of developing Clostridium difficile–
associated diarrhea. Journal of Critical Care, 29(4), 696.e11-696.e15. doi: 
10.1016/j.jcrc.2014.03.002 
Buonomo, E. L., & Petri, W. A. (2016). The microbiota and immune response during 




Burke, K. E., & Lamont, J. T. (2014). Clostridium difficile infection: A worldwide 
disease. Gut and Liver, 8(1), 1–6. doi: 10.5009/gnl.2014.8.1.1 
Burke, R. E., Juaez-Colunga, E., Levy, C., Prochazka, A. V., Coleman, E. A., & Ginde, 
A. A. (2015). Patient and hospitalization characteristics associated with increased 
post-acute care facility discharges from US hospitals. Medical Care, 56(6), 492-
500. doi:10.1097/MLR.0000000000000359 
Burns, N., & Grove, S. K. (2005). The practice of nursing research (5th ed.). St Louis, 
MO: Elsevier Saunders 
Carlson, M. D. a, & Morrison, R. S. (2009). Study design, precision, and validity in 
observational studies. Journal of Palliative Medicine, 12(1), 77–82. 
doi:10.1089/jpm.2008.9690 
Carrico, R.M., Bryant, K., Lessa, F., Limbago, B., Faurbank, L. L., Marz, J.F., ... 
Wiemken, T. (2013). Guide to preventing Clostridium difficile infections: APIC 
elimination guide. Retrieved from 
http://www.apic.org/Resource_/EliminationGuideForm/e3a85b7e-7ad8-4ab6-
9892-54aef516cf10/File/2013CDiffFinal.pdf 
Chang, J., Guy, M. C., Rosales, C., De Zapien, J. G., Staten, L. K., Fernandez, M. L., & 
Carvajal, S. C. (2013). Investigating social ecological contributors to diabetes 
within Hispanics in and underserved U. S.- Mexico border community. 
International Journal of Environmental Research and Public Health, 10(8), 3217-
3232. doi: 10.3390/ijerph10083217 
101 
 
Centers for Disease Control and Prevention. (2013). Antibiotic resistance threats in the 
United States, 2013. Retrieved from http://www.cdc.gov/drugresistance/pdf/ar-
threats-2013-508.pdf 
Centers for Disease Control and Prevention. (2015). Diabetes report card 2014. 
Retrieved from 
http://www.cdc.gov/diabetes/pdfs/library/diabetesreportcard2014.pdf 
Centers for Disease Control and Prevention. (2017). National diabetes statistics report, 
2017. Retrieved from https://www.cdc.gov/diabetes/pdfs/data/statistics/national-
diabetes-statistics-report.pdf 
Centers for Disease Control and Prevention (2016). Defining adult overweight and 
obesity. Retrieved from https://www.cdc.gov/obesity/adult/defining.html 
Centers for Medicare and Medicaid. (2016). 110 - Inpatient Rehabilitation Facility (IRF) 
Services. Medicare benefit policy manual chapter 1: Inpatient hospital services 
covered under Part A. Retrieved from https://www.cms.gov/Regulations-and-
Guidance/.../bp102c01.pdf 
Centers for Medicare and Medicaid. (2012). Inpatient rehabilitation therapy services: 
Complying with documentation. Retrieved from 
https://www.cms.gov/.../Inpatient_Rehab_Fact_Sheet_ICN905643.pdf 
Clark, M. L., & Utz, S. W. (2014). Social determinants of type 2 diabetes and health in 
the United States. World Journal of Diabetes, 5(3), 296-304. doi: 
10.4239/wjd.v5.i3.296 
Clooney, A. G., Bernstein, C. N., Leslie, W. D., Vagianos, K., Argent, M., Laserna-
102 
 
Mendieta, E. J., ... Targownik, L. E. (2016). A comparison of the gut microbiome 
between long-term users and non-users of proton pump inhibitors. Alimentary 
Pharmacology and Therapeutics, 43(9), 974-984. doi: 10.1111/apt.13568 
Cohen, S. H., Gerding, D. N., Johnson, S., Kelly, C. P., Loo, V. G., McDonald, L. C., ... 
Wilcox, M. H. (2010). Clinical practice guidelines for Clostridium difficile 
infection in adults: 2010 update by the society for healthcare epidemiology of 
America (SHEA) and the infectious diseases society of America (IDSA).  
Infection Control & Hospital Epidemiology, 31(05), 431-455. doi: 
10.1086/651677 
Creswell, J. W. (2009). Research design: Qualitative, quantitative, and mixed methods 
approaches (3rd. Laureate Education, Inc. Custom ed.). Thousand Oaks: CA: 
Sage 
Crocker, S. A. (2013). Diabetes and the Off-Reserve Aboriginal population in Canada 
(Master thesis). Available from ProQuest Dissertations & Theses Global. 
(1520045355) 
D’Argenio, V., & Salvatore, F. (2015). The role of the gut microbiome in the healthy 
adult status. Clinica Chimica Acta, 451, 97–102. doi: 10.1016/j.cca.2015.01.003 
Daneman, N., Guttmann, A., Wang, X., Ma, X., Gibson, D., & Stukel, T. A. (2015). The 
association of hospital prevention processes and patient risk factors with the risk 
of Clostridium difficile infection: A population-based cohort study. BMJ Quality 
& Safety, 24(7), 1-9. doi: 10.1136/bmjqs-2014-003863 
Dean, A. G, Sullivan K. M, Soe M. M. (2002). OpenEpi: open source epidemiologic 
103 
 
statistics for public health, [Version 3.01. Updated 2013/04/06]. Retrieved from 
www.OpenEpi.com 
de Groot, V., Beckerman, H., Lankhorst, G. J., & Bouter, L. M. (2003). How to measure 
comorbidity: A critical review of available methods. Journal of Clinical 
Epidemiology, 56(3), 221–229. doi: 10.1016/S0895-4356(02)00585-1 
DePestel, D. D., & Aronoff, D. M. (2013). Epidemiology of Clostridium difficile 
infection. Journal of Pharmacy Practice, 26(5), 464–475. doi: 
10.1177/0897190013499521 
Desai, K., Gupta, S. B., Dubberke, E. R., Prabhu, V. S., Browne, C., & Mast, T. C. 
(2016) Epidemiological and economic burden of Clostridium difficile in the 
United States: Estimates from a modeling approach. BMC Infectious Diseases, 
16(303). doi:10.1186/s12879-016-1610-3 
Deshpande, A., Pasupuleti, V., Thota, P., Pant, C., Rolston, D. D. K., Hernandez, A. V., 
… Fraser, T. G. (2015). Risk factors for recurrent Clostridium difficile infection: 
A systematic review and meta-analysis. Infection Control & Hospital 
Epidemiology, 36(4), 452–460. doi: 10.1017/ice.2014.88 
Dial, S., Alrasadi, K., Manoukian, C., Huang, A., & Menzies, D. (2004). Risk of 
Clostridium difficile diarrhea among hospital inpatients prescribed proton pump 
inhibitors: cohort and case–control studies. Journal of Canadian Medical 
Association, 171(1), 33–38. doi: 10.1503/cmaj.1040876 
Dodds, T. A., Martin, D. P., Stolov, W. C., & Deyo, R. A.  (1993). A validation of the 
functional independence measurement and its performance among rehabilitation 
104 
 
inpatients.  Archives of Physical Medicine and Rehabilitation, 74(5), 531-536.  
doi: 10.1016/0003-9993(93)90119-U 
Drugs.com (n.d.). Proton pump inhibitors.  Retrieved from http://www.drugs.com/drug-
class/proton-pump-inhibitors.html 
Durham, D.P., Olsen, M. A., Dubberke, E. R., Galvani, P., & Townsend, J.P. (2016). 
Quantifying transmission of Clostridium difficile within and outside healthcare 
settings. Emerging Infectious Diseases, 22(4), 608-616. doi: 
10.3201/eid2204.150455 
Eckert, C., Emirian, A., Le Monnier, A., Cathala, L., De Montclos, H., Goret, J., ... & 
Nebbad, B. (2015). Prevalence and pathogenicity of binary toxin–positive 
Clostridium difficile strains that do not produce toxins A and B. New microbes 
and New Infections, 3, 12-17. doi: 10.1016/j.nmni.2014.10.003 
Eke, W. (2013) Massachusetts universal health insurance: Outcomes, access, and quality 
for African Americans with type 2 diabetes [Doctoral dissertation]. Available 
from ProQuest Dissertations & Theses Global database (3601063) 
Eliakim-Raz, N., Fishman, G., Yahav, D., Goldberg, E., Stein, G. Y., Zvi, H. B., ... 
Bishara, J. (2015). Predicting Clostridium difficile infection in diabetic patients 
and the effect of metformin therapy: A retrospective, case–control study. 
European Journal of Clinical Microbiology & Infectious Diseases, 34(6), 1201-
1205. doi: 10.1007/s10096-015-2348-3 
Ellis, P. D. (2010). The essential guide to effect sizes: Statistical power, meta-analysis, 




Escobar, J. S., Klotz, B., Valdes, B. E., & Agudelo, G. M. (2014). The gut microbiota of 
Colombians differs from that of Americans, Europeans and Asians. BMC 
Microbiology, 14(311). doi: 10.1186/s12866-014-0311-6 
Eze, I. C., Schaffner, E., Fischer, E., Schikowski, T., Adam, M., Imboden, M., … Probst-
Hensch, N. (2014). Long-term air pollution exposure and diabetes in a population-
based Swiss cohort. Environment International, 70, 95–105. doi: 
10.1016/j.envint.2014.05.014 
Faleck, D. M., Salmasian, H., Furuya, E. Y., Larson, E. L., Abrams, J. A., & Freedberg, 
D. E. (2016). Proton pump inhibitors do not increase risk for Clostridium difficile 
infection in the intensive care unit. American Journal of Gastroenterology, 
111(11). 1641-1648. doi: 10.1038/ajg.2016.343; 
Field, A. (2013) Discovering statistics using IBM SPSS Statistics (4th Ed.). London: 
SAGE 
Frankfort-Nachmias, C., & Nachmias, D. (2008). Research methods in the social sciences 
(7th ed.). New York, NY: Worth 
Forouhi, N. G., & Wareham, N. J. (2014). Epidemiology of diabetes. Medicine, 42(12), 
698-702. doi: 10.1016/j.mpmed.2014.09.009 
Forslund, K., Hildebrand, F., Nielsen, T., Falony, G., Le Chatelier, E., Sunagawa, S., … 
Pedersen, O. (2015). Disentangling type 2 diabetes and metformin treatment 




Fowler, M. J. (2011). Microvascular and macrovascular complications of diabetes. 
Clinical Diabetes, 29(3), 116-122. doi: 10.2337/diaclin.29.3.116 
Fraze, T., Jiang, J., & Burgess, J. (2010). Hospital stays for patients with diabetes, 2008 
HCUP policy brief # 93. Agency for Healthcare Research and Quality. Retrieved 
from: http://www.hcup-us.ahrq.gov/reports/statbriefs/sb93.pdf 
Freedberg, D. E., Salmasian, H., Friedman, C., & Abrams, J. A. (2013). Proton pump 
inhibitors and risk for recurrent Clostridium difficile infection among inpatients. 
The American Journal of Gastroenterology, 108(11), 1794–801. doi: 
10.1038/ajg.2013.333 
Freeman, J., & Wilcox, M. H. (1999). Antibiotics and Clostridium difficile. Microbes and 
Infection, 1(5), 377-384. doi: 10.1016/S1286-4579(99)80054-9 
Gan, Y. (2013). Host susceptibility factors to bacterial infections in type2 diabetes. PLOS 
Pathogens, 9(5), e1003794. doi: 10.1371/journal.ppat.1003794 
Ganz, M. L., Wintfeld, N., Li, Q., Alas, V., Langer, J., & Hammer, M. (2014). The 
association of body mass index with the risk of type 2 diabetes: a case–control 
study nested in an electronic health records system in the United States. 
Diabetology & Metabolic Syndrome, 6(1), 50. doi: 10.1186/1758-5996-6-50 
Garcia, C., Feve, B., Ferre, S., Halimi, S., Baizri, H., Bordier, L., ... Mayaudon, H. 
(2010). Diabetes and inflammation: Fundamental aspects and clinical 
implications. Diabetes & Metabolism, 36(5), 327-338. doi: 
10.1016/j.diabet.2010.07.001 
Garcia, L., Lee, A., Hazzouri, A. Z., Neuhaus, J., Epstein, M., & Hann, M. (2015). The 
107 
 
impact of neighborhood socioeconomic position on prevalence of diabetes and 
pre-diabetes in older Latinos: The Sacramento area Latino study on aging. 
Hispanic Health Care International, 13(2), 77-85. doi: 10.1891/1540-
4153.13.2.77 
Gerding, D. N., Johnson, S., Rupnik, M., & Aktories, K. (2014). Clostridium difficile 
binary toxin CDT: mechanism, epidemiology, and potential clinical importance. 
Gut Microbes, 5(1), 15-27. doi: 10.4161/gmic.26854 
Gerrard, P., Goldstein, R., DiVita, M. A., Ryan, C. M., Mix, J., Niewczyk, P., ... & 
Schneider, J. C. (2013). Validity and reliability of the FIM instrument in the 
inpatient burn rehabilitation population. Archives of Physical Medicine and 
Rehabilitation, 94(8), 1521-1526. doi: 10.1016/j.apmr.2013.02.019 
Giaquinto, S., Palma, E., Maiolo, I., Piro, M. T., Roncacci, S., Sciarra, A., & Vittoria, E. 
(2001). Importance and evaluation of comorbidity in rehabilitation. Disability & 
Rehabilitation, 23(7), 296-299. doi:10.1080/096382801750143643 
Gilbert, J. A., Quinn, R. A., Debelius, J., Xu, Z. Z., Morton, J., Garg, N., … Knight, R. 
(2016). Microbiome-wide association studies link dynamic microbial consortia to 
disease. Nature, 535(7610), 94–103. doi: 10.1038/nature18850 
Gordon, D., Young, L. R., Reddy, S., Bergman, C., & Young, J. D. (2016). Incidence of 
Clostridium difficile infection in patients receiving high-risk antibiotics with or 
without a proton pump inhibitor. Journal of Hospital Infection, 92(2), 173-177. 
doi: 10.1016/j.jhin.2015.10.009 
Goudarzi, M., Seyedjavadi, S. S., Goudarzi, H., Aghdam, E. M., & Nazeri, S. (2014). 
108 
 
Clostridium difficile infection: epidemiology, pathogenesis, risk factors, and 
therapeutic options. Scientifica, 2014, 1–9. doi: 10.1155/2014/916826 
Granger, C. V. (2014).  Lessons learned through leadership.  PM & R, 6(6), 469-472.  
doi: 10.1016/j.pmrj.2014.05.008 
Gregory, K. E., & Radovinsky, L. (2012). Research strategies that result in optimal data 
collection the patient medical record. Applied Nursing Research, 25(2), 108-116.  
doi: 10.1016/j.apnr.2010.02.004 
Guillemin, I., Marrel, A., Lambert, J., Beriot-Mathiot, A., Doucet, C., Kazoglou, O., ... 
Arnould, B. (2014). Patients’ experience and perception of hospital-treated 
Clostridium difficile infections: a qualitative study. The Patient - Patient-Centered 
Outcomes Research, 7(1), 97-105. doi: 10.1007/s40271-013-0043-y 
Hassan, S. A., Rahman, R. A., Huda, N., Wan Bebaker, W. M., & Lee, Y. Y. (2013). 
Hospital acquired Clostridium difficile infection among patients with type 2 
diabetes in acute medical wards. Journal Royal College of Physicians of 
Edinburgh, 43(2), 103-107. doi: 10.4997/JRCPE.2013.203 
He, M., Miyajima, F., Roberts, P., Ellison, L., Pickard, D. J., Martin, M. J., ... D'Arc, S. 
(2013). Emergence and global spread of epidemic healthcare-associated 
Clostridium difficile. Nature genetics, 45(1), 109-113. doi: 10.1038/ng.2478 
Healthcare Cost and Utilization Project. (2016). Overview of the National (Nationwide) 
Inpatient Sample (NIS). Retrieved from http://www.hcup-
us.ahrq.gov/nisoverview.jsp 
Hill, J. O., Galloway, J. M., Goley, A., Marrero, D. G., Minners, R., Montgomery, B., … 
109 
 
Aroda, V. R. (2013a).  Scientific statement: Socioecological determinants of 
prediabetes and type 2 diabetes. Diabetes Care, 36(8), 2430–2439. doi: 
10.2337/dc13-1161 
Hill, J., Nielsen, M., & Fox, M. H. (2013b). Understanding the social factors that 
contribute to diabetes: a means to informing health care and social policies for the 
chronically ill. The Permanente Journal, 17(2), 67–72. doi:10.7812/TPP/12-099 
Henrich, T. J., Krakower, D., Bitton, A., & Yokoe, D. S. (2009). Clinical risk factors for 
severe Clostridium difficile-associated disease. Emerging Infectious Diseases, 
15(3), 415-422. doi: 10.3201/edi1503.080321 
Hensgens, M. P., Goorhuis, A., Dekkers, O. M., & Kuijper, J., (2012) Time interval of 
increased risk for Clostridium difficile infection after exposure to antibiotics. 
Journal of Antimicrobial Chemotherapy, 67(3), 742–748. doi: 10.1093/jac/dkr508 
Huang, Y. L., Chassard, C., Hausmann, M., von Itzstein, M., & Hennet, T. (2015). Sialic 
acid catabolism drives intestinal inflammation and microbial dysbiosis in mice. 
Nature communications, 6, 8141. doi: 10.1038/ncomms9141 
Huang, C., & Wang, X. (2009). Increased use of protein pump inhibitors in patients with 
diabetes and neuropathy [Letter to Editor]. Endocrine Practice, 15(6), 653-654. 
Doi: 10.4158/ep.15.6.653 
Hunter, J. C., Mu, Y., Dumyati, G. K., Farley, M. M., Winston, L. G., Johnston, H. L., ... 
& Lessa, F. C. (2016). Burden of nursing home-onset Clostridium difficile 
infection in the United States: Estimates of incidence and patient outcomes. Open 
Forum Infectious Diseases, 3(1). doi: 10.93/ofid/ofv196 
110 
 
Ichiro, K., Daniels, N., & Robinson, D. E. (2005). Health disparities by race and class: 
Why both matter. Health Affairs 25(2), 343-352. doi: 10.1377/hlthaff.24.2.343 
Iizuka, M., Itou, H., Konno, S., Chihara, J., Tobita, M., Oyamada, H., ... & Watanabe, S. 
(2004). Elemental diet modulates the growth of Clostridium difficile in the gut 
flora. Alimentary pharmacology & therapeutics, 20(s1), 151-157.doi: 
10.1111/j.1365-2036.2004.01969.x 
Imhann, F., Bonder, M. J., Vila, A. V., Fu, J., Mujagic, Z., Vork, L., ...  Dijkstra, G. 
(2016). Proton pump inhibitors affect the gut microbiome. Gut, 65(5), 740-748. 
doi: 10.1136/gutjul-2015-310376 
International Federation of Diabetes. (2014). Diabetes atlas (6th ed.).  Retrieved from 
http://www.idf.org/sites/default/files/EN_6E_Atlas_Full_0.pdf 
Janarthanan, S., Ditah, I., Phil, M., Adler, D. G., & Ehrinpreis, M. N. (2012). Clostridium 
difficile-associated diarrhea and proton pump inhibitor therapy: A meta-analysis. 
American Journal of Gastroenterology, 107(7), 1001-1010. doi: 
10.1038/ajg.2012.179 
Janezic, S., Marín, M., Martín, A., & Rupnik, M. (2015). A new type of toxin A-negative, 
toxin B-positive Clostridium difficile strain lacking a complete tcdA gene. 
Journal of clinical microbiology, 53(2), 692-695. doi: 10.1128/JCM.02211-14 
Jandhyala, S. M., Talukdar, R., Subramanyam, C., Vuyyuru, H., Sasikala, M., & Reddy, 
D. N. (2015). Role of the normal gut microbiota. World Journal of 
Gastroenterology, 21(29), 8787-8803. doi: 10.3748/wjg.v21.i29.8787 
Jääskeläinen, I. H., Hagberg, L., Forsblom, E., & Järvinen, A. (2017). Microbiological 
111 
 
etiology and treatment of complicated skin and skin structure infections in 
diabetic and nondiabetic patients in a population-based study. Open Forum 
Infectious Diseases, 4(2). doi: 10.1093/ofid/ofx044 
Jarvis, W. R., Schlosser, J., Jarvis, A. A., & Chinn, R. Y. (2009). National point 
prevalence of Clostridium difficile in US health care facility inpatients, 2008. 
American Journal of Infection Control, 37(4), 263-270. doi: 
10.1016/j.ajic.2009.01.001 
Jenkins, T. C., Knepper, B. C., Moore, S. J., O’Leary, S. T., Caldwell, B., Saveli, C. C., 
… Burman, W. J. (2014). Antibiotic prescribing practices in a multicenter cohort 
of patients hospitalized for acute bacterial skin and skin structure infection. 
Infection Control & Hospital Epidemiology, 35(10), 1241–1250.  
doi:10.1086/678056 
Jump, R. L., Pultz, M. J., Donskey, C. J. (2007). Vegetative Clostridium difficile survives 
in room air on moist surfaces and in gastric content with reduced acidity: A 
potential mechanism to explain the association between proton pump inhibitors 
and C. difficile-associated diarrhea? Antimicrobial Agents and Chemotherapy, 
51(8). 2883-2887. doi:10.1128AAC.01443-06  
Karlsson, F. H., Tremaroli, V., Nookaew, I., Bergström, G., Behre, C. J., Fagerberg, B., 
... Bäckhed, F. (2013). Gut metagenome in European women with normal, 
impaired and diabetic glucose control. Nature, 498(7452), 99-103. doi: 
10.1038/nature12198 
Kelly, C. P., & Lamont, J. T. (1998). Clostridium difficile infection. Annual Review of 
112 
 
Medicine, 49(1), 375–390. doi: 10.1146/annurev.med.49.1. 
Khalili, P., Sundström, J., Jendle, J., Lundin, F., Jungner, I., & Nilssen, P. M. (2014).  
Sialic acid and incidence of hospitalization for diabetes and its complications 
during 40-years of follow-up in a large cohort: The Värmland survey.  Primary 
Care Diabetes, 8(4), 352-357. doi: 10.1016/j.pcd.2014.06.002 
Kivimäki, M., Virtanen, M., Kawachi, I., Nyberg, S. T., Alfredsson, L., Batty, G. D., … 
Jokela, M. (2015). Long working hours, socioeconomic status, and the risk of 
incident type 2 diabetes: A meta-analysis of published and unpublished data from 
222120 individuals. The Lancet Diabetes and Endocrinology, 3(1), 27–34. doi: 
10.1016/S2213-8587(14)70178-0 
Krieger, N. (1994). Epidemiology and the web of causation: Has anyone seen the spider? 
Social science & medicine, 39(7), 887-903 doi: 10.1016/0277-9536(94)90202-X 
Krieger, N. (2001). Theories for social epidemiology in the 21st century: an ecosocial 
perspective. International Journal of Epidemiology, 30(4), 668–677. doi: 
10.1093/ije/30.4.668 
Krieger, N. (2005). Embodiment: a conceptual glossary for epidemiology. Journal of 
Epidemiology and Community Health, 59(5), 350–355. doi: 
10.1136/jech.2004.024562 
Krieger, N. (2008). Proximal, distal, and the politics of causation: What’s level got to do 
with it? American Journal of Public Health, 98(2), 221–230. doi: 
10.2105/AJPH.2007.111278 
Krieger, N. (2011). Epidemiology and the people’s health: Theory and context. New 
113 
 
York, NY: Oxford University Press. 
Krieger, N. (2012). Methods for the scientific study of discrimination and health: An 
ecosocial approach. American Journal of Public Health, 102(5), 936–945. 
doi:10.2105/AJPH.2011.300544 
Krieger, N., Waterman, P. D., Kosheleva, A., Chen, J. T., Smith, K. W., Carney, D. R., ... 
& Freeman, E. R. (2013). Racial discrimination & cardiovascular disease risk: My 
body my story study of 1005 US-born black and white community health center 
participants (US). PLoS ONE 8(10), e77174. doi: 10.1371/journal.pone.0077174 
Krishnan, B., Babu, S., Walker, J., Walker, A. B., & Pappachan, J. M. (2013). 
Gastrointestinal complications of diabetes mellitus. World Journal of Diabetes, 
4(3), 51-63. doi: 10.4239/wjd.v4.i3.51 
Krishnan, S., Cozier, Y. C., Rosenberg, L., & Palmer, J. R. (2010). Socioeconomic status 
and incidence of type 2 diabetes: Results from the black women’s health study. 
American Journal of Epidemiology, 171(5), 564–570. doi:10.1093/aje/kwp443 
Kuehne, S. A., Cartman, S. T., Heap. J.T., Kelly, M.L., Cockayne, A., & Minton, N.P. 
(2010). The role of toxin A and toxin B in Clostridium difficile infection. Nature 
467. 711-714. doi: 10.1038/nature09397 
Kurti, Z., Lovasz, B. D., Mandel, M. D., Csima, Z., Golovics, P. A., Csako, B. D., ... 
Lakatos, P. L. (2015). Burden of Clostridium difficile infection between 2010 
and2013: Trends and outcomes from an academic center in Eastern Europe. 




Kwok, C. S., Arthur, N. K., Anibueze, C. I., Singh, S., Cavallazzi, R., & Loke, Y. K. 
(2012). Risk of Clostridium difficile infection and acid suppressing drugs and 
antibiotics.  Meta-analysis. American Journal of Gastroenterology, 107(7), 1011-
1019.  doi: 10.1038/ajg.2012.108 
Kyne, L., Sougioultzis, S., McFarland, L. V., & Kelly, C. P. (2002). Underlying disease 
severity as a major risk factor for nosocomial Clostridium difficile diarrhea.  
Infection Control and Hospital Epidemiology, 23(11), 653-659. doi: 
10.1086/501989 
Larentis, D. Z., Rosa, R. G., dos Santos, R. P., & Goldani, L. Z. (2015) Outcomes and 
risk factors associated with Clostridium difficile diarrhea n hospitalized adult 
patients. Gastroenterology Research and Practice, 2015(346341). doi: 
10.1155/2015/346341 
Larsen, N., Vogensen, F. K., van den Berg, F. W., Nielsen, S. S., Andreasen, A. S., 
Pedersen, B.K., … Jakobsen, M. (2010). Gut microbiota in human adults with 
type 2 diabetes differs from non-diabetic adults. PLoS ONE, 5(2), e9085. doi: 
101371/journal.phone.0009085 
Lederberg, J., McCray, A.T.  (2001). "Ome Sweet 'Omics—a genealogical treasury of 
words". Scientist 15: 8.  Retrieved from http://www.the-
scientist.com/?articles.view/articleNo/13313/title/-Ome-Sweet--Omics---A-
Genealogical-Treasury-of-Words/  
Lee, H. C., Kim, K. O., Jeong, Y. H., Lee, S. H., Jang, B. I., & Kim, T. N. (2016). 
Clinical outcomes in hospitalized patients with Clostridium difficile infection by 
115 
 
age group. Korean Journal of Gastroenterology, 67(2), 81-86. doi: 
10.4166/kjg.2016.67.2.81 
Lee, T. C., Glynn, R. J., Peña, J. M., Paynter, N. P., Conen, D., Ridker, P. M., … Albert, 
M. A. (2011). Socioeconomic status and incident type 2 diabetes mellitus: data 
from the Women’s Health Study. PloS One, 6(12), e27670. doi: 
10.1371/journal.pone.0027670 
Lessa, F. C., Mu, Y. Bamberg, W. M., Beldavs, Z. G., Dumyati, G. K., Dunn, J. R., ... 
McDonald, L. C. (2015). Burden of Clostridium difficile infection in the United 
States.  New England Journal of Medicine, 372(9), 825-34.  doi: 
10.1056/NEJMoa1408913 
Leung, J., Burke, B., Ford, D., Garvin, G., Korn, K., Sulis, C., & Bhadelia, N. (2013). 
Possible association between obesity and Clostridium difficile infection. 
Emerging Infectious Diseases 19(11), 1791-1796. doi: 10.3201/eid1911.130618 
Leung, M. Y., Carlsson, N. P., Colditz, G. A., & Chang, S. H. (2016). The burden of 
obesity on diabetes in the United States: Medical expenditure panel survey, 2008 
to 2012. Value in Health, 20(1), 77-84. doi: 10.1016/j.jval.2016.08.735 
Lin, H.-J., Hung, Y.-P., Liu, H.-C., Lee, J.-C., Lee, C.-I., Wu, Y.-H., … Ko, W.-C. 
(2015). Risk factors for Clostridium difficile-associated diarrhea among 
hospitalized adults with fecal toxigenic C. difficile colonization. Journal of 
Microbiology, Immunology, and Infection 48(2), 183–9. doi: 
10.1016/j.jmii.2013.08.003  
Linn, B. S., Linn M. W. & Gurel, L. (1968). Cumulative illness rating scale. Journal of 
116 
 
the American Geriatrics Society, 18(6), 662-626. doi: 10.1111/j.1532-
5415.1968.tb02103.x 
Loo, V.G., Bourgault.  A., Poirier, L., Lamothe, F., Michaud, S., Turgeon, N., ... Dascal, 
A. (2011). Host and pathogen factors for Clostridium difficile infection and 
colonization.  New England Journal of Medicine, 365(18), 1693-1703. doi: 
10.1056/NEJMoa1012413 
Magliano, D. J., Harding, J. L., Cohen, K., Huxley, R. R., Davis, W. A., & Shaw, J. E. 
(2015). Excess risk of dying from infectious causes in those with type 1 and type 
2 diabetes. Diabetes Care, 38(7), 1274–80. doi: 10.2337/dc14-2820 
Martin, E. T., Kaye, K. S., Knott, C., Nguyen, H., Santarossa, M., Evans, R., … Jaber, L. 
(2016). diabetes and risk of surgical site infection: A systematic review and meta-
analysis. Infection Control & Hospital Epidemiology, 37(1), 88–99. 
doi:10.1017/ice.2015.249 
Mao, E. J., Kelly, C. R., & Machan, J. T. (2015). Racial differences in Clostridium 
difficile infection rates are attributable to disparities in health care access. 
Antimicrobial Agents and Chemotherapy, 59(10), 6283-6287. doi: 
10.1128/AAC.00795-15 
Magill, S. S., Edwards, J. R., Bamberg, W., Beldvas, Z. G., Dumyati, G., Kainer, M. A., 
... Fridkin, S. K. (2014).  Multi-state prevalence survey of health care-associated 
infections. New England Journal of Medicine, 370(13), 1198-1208.  doi: 
10.1056/NEJMoa1306801 
Marciniak, C., Chen, D., Stein, A. C., & Semik, P.E. (2006). Prevalence of Clostridium 
117 
 
difficile colonization at admission to rehabilitation. Archives of Physical & 
Medical Rehabilitation, 87(8), 1086-1090. doi: 10.1016/j.apmr.2006.03.020 
Marley, T. L. (2013). Indigenous knowledge, land, history, and health: The construction 
of diabetes on the White Mountain Apache Indian Reservation [Doctoral 
dissertation]. Available from ProQuest Dissertations and Theses Global database. 
(1427854655) 
Meng, Y. Y., Pickett, M. C., Babey, S. H., Davis, A. C., & Goldstein, H. (2014). Diabetes 
tied to a third of California hospital stays, driving health care costs higher. UCLA 
Center for Health Policy Research Policy Brief (PB2014-3), 1-7. Retrieved from 
http://healthpolicy.ucla.edu/publications/search/pages/detail.aspx?pubID=1278 
Menke, A., Casagrande, S., Geiss, L., & Cowie, C. (2015). Prevalence of and trends in 
diabetes among adults in the United States, 1988-2012. Journal of the American 
Medical Association, 314(10), 1021–1029. doi:10.1001/jama.2015.10029 
McGlone, S. M., Bailey, R. R., Zimmer, S. M., Popovich, J. P., Tian, Y., Ufberg, P., ... 
Lee, B. Y. (2012). Economic burden of Clostridium difficile. Clinical 
Microbiology and Infection, 18(3), 282-289. doi: 10.1111/j.1469-
0691.2011.03571.x 
McLaren, L., & Hawe, P. (2005). Ecological perspectives in health research. Journal of 
Epidemiology and Community Health, 59(1), 6-14. doi: 
10.1136/jech.2003.018044 
Miller, M., Gravel, D., Mulvey, M., Taylor, G., Boyd, D., Simor, A., ... Kelly, S. (2010). 
Health care–associated Clostridium difficile infection in Canada: Patient age and 
118 
 
infecting strain type are highly predictive of severe outcome and mortality. 
Clinical Infectious Diseases, 50(2), 194-201. doi:  10.1086/649213 
Molloy, M. J., Bouladoux, N., & Belkaid, Y. (2012, February). Intestinal microbiota: 
shaping local and systemic immune responses. In Seminars in immunology (Vol. 
24, No. 1, pp. 58-66). doi: 10.1016/j.smim.2011.11.008 
Monot, M., Eckert, C., Lemire, A., Hamiot, A., Dubois, T., Tessier, C., … Dupuy, B. 
(2015). Clostridium difficile: New insights into the evolution of the pathogenicity 
locus. Scientific Reports, 5, 15023. doi: 10.1038/srep15023 
Morrison, R. H., Hall, N. S., Said, M., Rice, T., Groff, H., Brodine, S. K., … Lederman, 
E. R. (2011). Risk factors associated with complications and mortality in patients 
with Clostridium difficile infection. Clinical Infectious Diseases, 53(12), 1173–
1178. doi: 10.1093/cid/cir668 
Mueller, S., Saunier, K., Hanish, C., Norin, E., Alm, L., Midtvedt, T., ... Blaut, M. 
(2006). Differences in fecal microbiota in different European study populations in 
relation to age, gender, and country: A cross-sectional study. Applied and 
Environmental Microbiology, 72(2), 1027-1033. doi: 10.1128/AEM.72.2.1027-
1033.2006 
Muller, L. M., Gorter, K. J., Hak, E., Goudzwaard, W. L., Schellevis, F. G., & 
Hoepelman, A. I., & Rutten, G. E. (2005). Increased risk of common infections in 
patients with type 1 and type 2 diabetes mellitus, Clinical Infectious Diseases, 
41(3), 281-288. doi: 10.1086/431587 
Murphy, C. R., Avery, T. R. Dubberke, E. R., & Huang, S. S. (2012). Frequent hospital 
119 
 
readmissions for Clostridium difficile infection and the impact on estimates of 
hospital-associated C. difficile burden. Infection Control & Hospital 
Epidemiology, 33(1), 20-28. doi: 10.1086/663209 
Mutters, R., Nonnenmacher, C., Susin, C., Albrecht, U., Kropatsch, R., & Schumacher, S. 
(2009). Quantitative detection of Clostridium difficile in hospital environmental 
samples by real-time polymerase chain reaction. Journal of Hospital Infection, 
71(1), 43-48. doi: 10.1016/j.jhin.2008.10.021 
Mylotte, J. M., Graham, R., Kahler, L., Young, L., & Goodnough, S. (2000).  
Epidemiology of nosocomial infection and resistant organisms in patients 
admitted for the first time to an acute rehabilitation unit.  Clinical Infectious 
Diseases, 30(3), 425-432.  doi: 10.1086/313708 
Mylotte, J. M., Russell, S., Sackett, B., Vallone, M., & Antalek, M. (2013). Surveillance 
for Clostridium difficile infection in nursing homes. Journal of the American 
Geriatrics Society, 61(1), 122-125. doi: 10.1111/jgs.12041 
Nerandzic, M. M., Pultz, M. J., & Donskey, C. J. (2009). Examination of potential 
mechanisms to explain the association between proton pump inhibitors and 
Clostridium difficile infection. Antimicrobial agents and Chemotherapy, 53(10), 
4133-4137. doi: 10.1128/AAC.00252-09 
Ng, M. K., Ferreyra, J. A., Higginbottom, S.K. Lynch, J. B., Kashyap, P. C., Gopinath, 
S., ... Sonnenburg, J.L. (2013). Microbiota-liberated host sugars facilitate post-




Novack, L., Kogan, S., Gimpelevich, L., Howell, M., Borer, A., Kelly, C. P., ... Novack, 
V. (2014). Acid suppression therapy does not predispose to Clostridium difficile 
infection: The case of the potential bias. PLoS ONE, 9(10), e110790. doi:  
10.1371/journal.ponr.0110790 
Nguyen, N. T., Nguyen, X.-M. T., Lane, J., & Wang, P. (2011). Relationship Between 
Obesity and Diabetes in a US Adult Population: Findings from the National 
Health and Nutrition Examination Survey, 1999–2006. Obesity Surgery, 21(3), 
351–355. doi: 10.1007/s11695-010-0335 
O’Keefe, S. J. (2010). Tube feeding, the microbiota, and Clostridium difficile infection. 
World Journal of Gastroenterology, 16(2), 139-142. doi: 10.3748/wjg.v16.i2.139 
Office of Disease Prevention and Health Promotion, (2016) National targets and metrics. 
National action plan to prevent health care-associated infections: Road map to 
elimination. Retrieved from https://health.gov/hcq/prevent-hai-measures.asp 
Olanipekun, T. O., Salemi, J. L., de Grubb, M. C., Gonzalez, S. J., & Zoorob, R. J. 
(2016). Clostridium difficile infection in patients hospitalized with type 2 diabetes 
mellitus and its impact on morbidity, mortality, and the costs of inpatient care. 
Diabetes Research and Clinical Practice, 116, 68-79. doi: 
10.1016/j.diabres.2016.04.021 
Olsen, M. A., Young-Xu, Y., Stwalley, D., Kelly, C. P., Gerding, D. N., Saeed, M. J., ... 
& Dubberke, E. R. (2016). The burden of Clostridium difficile infection: 
estimates of the incidence of CDI from US administrative databases. BMC 
Infectious Diseases, 16(177). doi: 10.1186/s12879-016-1501-7 
121 
 
Ottenbacher, K. J., Karmarkar, A., Graham, J. E., Kuo, Y., Deutsch, A., Reistetter, T. A., 
… Granger, C. V. (2015). Thirty-day hospital readmission following discharge 
from postacute rehabilitation in fee-for-service Medicare patients. Journal of the 
American Medical Association, 1137(6), 604–614. doi:10.1001/jama.2014.8 
Owens Jr., R. C., Donskey, C. J., Gaynes, R. P., Loo, V. G., & Muto, C. A. (2008). 
Antimicrobial‐associated risk factors for Clostridium difficile infection. Clinical 
Infectious Diseases, 46(s1), S19–S31. doi: 10.1086/521859 
Patel, U. C., Wieczorkiewicz, J. T., & Tuazon, J. (2016). Evaluation of advanced age as a 
risk factor for severe Clostridium difficile infection. Journal of Clinical 
Gerontology & Geriatrics, 7(1), 12-16. doi: 10.1016/j.jcgg.2015.06.003 
Patterson, E., Cryan, J. F., Fitzgerald, G. F., Ross, R. P., Dinan, T. G., & Stanton, C. 
(2014). Gut microbiota, the pharmabiotics they produce and host health. 
Proceedings of the Nutrition Society, 73(4), 477-489. doi: 
10.1017/S0029665114001426 
Pechal, A., Lin, K., Allen, S., & Reveles, K. (2016). National age group trends in 
Clostridium difficile infection incidence and health outcomes in united states 
community hospitals. BMC Infectious Diseases, 16:682:.  
doi:10.1186/s12879-016-2027-8 
Peleg, A. Y., Weerarathna, T., McCarthy, J. S., & Davis, T. M. (2007). Common 
infections in diabetes: pathogenesis, management and relationship to glycaemic 




Phillips, J. C., Webel, A., Rose, C. D., Corless, I. B., Sullivan, K. M., Voss, J., ... & 
Iipinge, S. (2013). Associations between the legal context of HIV, perceived 
social capital, and HIV antiretroviral adherence in North America. BMC Public 
Health, 13(1), 1. doi: 10.1186/1471-2458-13-736 
Pruitt, R. N., & Lacy, D. B. (2012). Toward a structural understanding of Clostridium 
difficile toxins, A & B. Frontiers in Cellular and Infection Microbiology, 2(28), 
1-14. doi: 10.3389/fcimb.2012.00028 
Qin, J., Li, Y., Cai, Z., Li, S., Zhu, J., Zhang, F., ... Wang, J. (2012a). A metagenome-
wide association study of gut microbiota in type 2 diabetes. Nature, 490(7418), 
55-60. doi: 10.1038/nature11450 
Qin, J., Li, Y., Cai, Z., Li, S., Zhu, J., Zhang, F., ... Wang, J. (2012b). A metagenome-
wide association study of gut microbiota in type 2 diabetes [Supplemental 
material] Nature, 490(7418), 1-38. doi: doi:10.1038/nature11450 
Qu, H., & Jiang, Z. (2014). Clostridium difficile infection in diabetes. Diabetes Research 
and Clinical Practice, 105(2014), 285-294. doi: 10.1016/j.diabres.2014.06.002 
Rahman, I. U., Malik, S. A., Bashir, M., Khan, R. U., & Idrees, M. (2011). Monotherapy 
with metformin or glimepiride and changes in serum sialic acid in type 2 diabetes 
mellitus. British Journal of Diabetes and Vascular Disease, 11(3), 137–140. Doi: 
10.1177/1474651411412863  
Rajilić-Stojanović, M. (2013). Function of the microbiota. Best Practice & Research 
Clinical Gastroenterology, 27(1), 5-16. doi: 10.1016/j.bpg.2013.03.006 
Rao, K., Micic, D., Chenoweth, E., Deng, L., Galecki, A. T., Ring, C., … Malani, P. N. 
123 
 
(2013). Poor functional status as a risk factor for severe Clostridium difficile 
infection in hospitalized older adults. Journal of the American Geriatrics Society, 
61(10), 1738–1742. doi: 10.1111/jgs.12442 
Rehabilitation Institute of Chicago [RIC].  (2010). Rehab measures: Functional 
independence measure.  Retrieved from http://www.rehabmeasures.org 
Ricciardi, R., Nelson, J., Griffith, J.L., & Concannon, T. W. (2012). Do admissions and 
discharges to long term care facilities influence hospital burden of Clostridium 
difficile infections. Journal of Hospital Infection, 80(2),156-161. doi: 
10.1016/j.jhin.2011.11.002 
Rothman, K. J., Greenland, S., & Lash, T. L. (Eds.) (2008). Modern Epidemiology (3rd 
ed.). Philadelphia, PA: Lippincott Williams & Wilkins 
Rothman, K. J., Greenland, S., Poole, C., & Lash, T. L. (2008). Causation and causal 
inference. In K. J. Rothman, S. Greenland, & T. L. Lash (Eds.), Modern 
Epidemiology (3rd ed., pp. 5-31). Philadelphia, PA: Lippincott Williams & 
Wilkins 
Salvi, F., Miller, M. D., Grilli, A., Giorgi, R., Towers, A.L., Morichi, V., ... Dessí-
Fulgheri, P. (2008).  A manual of guidelines to score the modified cumulative 
illness rating scale and its validation in acute hospitalized elderly patients.  
Journal of the American Geriatrics Society, 56(10), 1926-1931. doi: 
10.1111/j.1532-5415.2008.01935.x 
Santelli, J. F. (2013).  Ethical issues in health promotion research.  In R. A. Crosby, R. J. 
DiClemente, & L. F. Salazar (Eds.) Research methods in health promotion 
124 
 
[Custom ed.]. San Francisco, CA: Jossey-Bass  
Satariano, W. A. (2006). Aging, health, and the environment: An ecological model. In 
Epidemiology of aging: An ecological approach. Sudbury, MA: Jones & Bartlett 
Scheurer, D. B., Hicks, L. S., Cook, E. F., & Schnipper, J. L. (2007). Accuracy of ICD-9 
coding for Clostridium difficile infections: a retrospective cohort. Epidemiology 
and Infection, 135(6), 1010–1013. doi: 10.1017/S0950268806007655 
Schmidt, M. I., Duncan, B. B., Sharrett, A. R., Lindberg, G., Savage, P. J., Offenbacher, 
S., ... Heiss, G. (1999). Markers of inflammation and prediction of diabetes 
mellitus in adults (Atherosclerosis Risk in Communities study): a cohort study. 
The Lancet, 353(9165), 1649-1652. http://dx.doi.org/10.1016/S0140-
6736(99)01046-6 
Schneiderman, N., Ironson, G., & Siegel, S. D. (2005). Stress and health: Psychological, 
behavioral, and biological determinants. Annual Review of Clinical Psychology, 
1(1), 607-628. doi: 10.1146/annurev.clinpsy.1.102803.144141 
Schubert, A. M., Rogers, M. A., Ring, C., Mogle, J., Petrosino, J. P., Young, V. B., … 
Schloss, P. D. (2014). Microbiome data distinguish patients with Clostridium 
difficile infection and non- C. difficile -associated diarrhea from healthy controls. 
mBio, 5(3), 1–9. doi:10.1128/mBio.01021-14 
Seto, C. T., Jeraldo, P., Orenstein, R., Chia, N., & DiBaise, J. K. (2014). Prolonged use of 
a proton pump inhibitor reduces microbial diversity: implications for Clostridium 
difficile susceptibility. Microbiome, 2(1),42. doi: 10.1186/2049-2618-2-42 
Shah, B. R., & Hux, J. E. (2003). Quantifying the risk of infectious diseases for people 
125 
 
with diabetes. Diabetes Care, 26(2), 510-513. doi: 10.2337/diacare.26.2.510 
Shah, S., Lewis, A., Leopold, D., Dunstan, F., & Woodhouse, K. (2000). Gastric acid 
suppression does not promote clostridial diarrhoea in the elderly. QJM, 93(3), 
175-181. doi: 10.1093/qjmed/93.3.175 
Shakov, R., Salazar, R. S., Kaqunye, S. K., Buddora, Q. J., & DeBan, V. A. (2011). 
Diabetes mellitus as a risk factor for recurrence of Clostridium difficile infection 
in the acute care hospital setting. American Journal of Infection Control, 39(3), 
194-198.  doi: 10.1016/j.ajic.2010.08.017 
Shavers, V. L., Klein, W. P., & Fagan, P. (2012). Research on race/ethnicity and health 
care discrimination: Where we are and where we need to go. American Journal of 
Public Health, 102(5), 930-932. doi:10.2105/AJPH.2012.300708 
Smith, K. F., Dobson, A. P., McKenzie, F. E., Real, L. A., Smith, D. L., & Wilson, M. L. 
(2005). Ecological theory to enhance infectious disease control and public health 
policy. Frontiers in Ecology and the Environment, 3(1), 29-37. doi: 
10.1890/1540-9295(2005)003[0029:ETTEID]2.0.CO;2 
Steele, J., Chen, K., Sun, X., Zhang, Y., Wang, H., Tzipori, S., & Feng, H. (2012). 
Systemic dissemination of Clostridium difficile toxins A and B is associated with 
severe, fatal disease in animal models. Journal of Infectious Disease, 205(3), 384-
391. doi: 10.1093/infdis/jir748  
Steiner, C. A., & Friedman, B. (2013). Hospital utilization, costs, and mortality for adults 
with multiple chronic conditions, Nationwide inpatient sample, 2009. Preventing 
Chronic Disease, 10, E62. doi: 10.5888/pcd10.120292 
126 
 
Stevens, V., Dumyati, G., Fine, L. S., Fisher, S. G., & Van Wijngaarden, E. (2011). 
Cumulative antibiotic exposures over time and the risk of Clostridium difficile 
infection. Clinical Infectious Diseases, 53(1), 42-48. doi: 10.1093/cid/cir301 
Stewart, D. B., & Hollenbeak, C. S. (2011) Clostridium difficile colitis: Factors 
associated with outcome and assessment of mortality at a national level. Journal 
of Gastrointestinal Surgery, 15(9), 1548-1555. doi: 10.1007/s11605-011-1615-6 
Stringhini, S., Zaninotto, P., Kumari, M., Kivimäki, M., & Batty, G. D. (2016). 
Lifecourse socioeconomic status and type 2 diabetes: the role of chronic 
inflammation in the English longitudinal study of ageing. Scientific Reports, 6, 
24780. doi: 10.1038/srep24780 
Susser, M., & Susser, E. (1996). Choosing a future for epidemiology: II. From black box 
to Chinese boxes and eco-epidemiology. American Journal of Public Health, 
86(5), 674-677. Retrieved from http://ajph.aphapublications.org 
Szklo, M., & Nieto, F. J. (2014). Epidemiology: Beyond the basics (3rd ed.). Burlington, 
MA: Jones & Bartlett Learning 
Tabak, Y. P., Zilberberg, M. D., Johannes, R. S., Sun, X., & McDonald, L. C. (2013). 
Attributable burden of hospital-onset Clostridium difficile infection: a propensity 
score matching study. Infection Control & Hospital Epidemiology, 34(06), 588-
596. doi: 10.1086/670621 
Tartof, S, Yn, K. C., Wei, R., Tseng, H. F., Jacobson, S. J., & Rieg, G. K. (2014). 
Incidence of polymerase chain reaction-diagnosed Clostridium difficile in a large 




Theriot, C. M., Koenigsknecht t, M. J., Carlson, P. E., Hatton, G. E., Nelson, A. M., Li, 
B., … Young, V. B. (2014). Antibiotic-induced shifts in the mouse gut 
microbiome and metabolome increase susceptibility to Clostridium difficile 
infection. Nature Communications, 5. doi: 10.1038/ncomms4114 
Tleyjeh, I. M., Bin Abdulhak, A. A., Riaz, M., Alasmari, F. A., Garbati, M. A., 
AlGhamdi, M., ... Sutton, A. J. (2012). Association between proton pump 
inhibitor therapy and Clostridium difficile infection: A contemporary systematic 
review and meta-analysis. PLoS One 7(12), e50836. doi: 
10.1371/journal.pone.0050836 
Trickett, E. J., & Beehler, S. (2013). The ecology of multilevel interventions to reduce 
social inequalities in health. American Behavioral Scientist, 57(8), 1227–1246. 
doi: 10.1177/0002764213487342 
The White House. (2015). National action plan for combating antibiotic-resistant 
bacteria. Retrieved from 
https://www.whitehouse.gove/sites/default/files/docs/national_action_plan_for_co
mbating_antibiotic-resistant_bacteria.pdf 
Valderas, J. M., Starfield, B., Sibbald, B., Salisbury, C., & Roland, M. (2009). Defining 
comorbidity: Implications for understanding health and health services. Annals of 
Family Medicine, 7(4), 357–363. doi: 10.1370/afm.983 
Vandenbroucke, J. P., & Pearce, N. (2012). Case-control studies: Basic concepts. 
International Journal of Epidemiology, 41(5), 1480–1489. doi:10.1093/ije/dys147 
128 
 
van Werkhoven, C. H., van der Tempel, J., Jajou, R. Thijsen, S. F., Diepersloot, R. J., 
Bonten, M.J., ... Oosterheert, J.J. (2015). Identification of patients at high risk for 
Clostridium difficile infection: Development and validation of a risk prediction 
model in hospitalized patients treated with antibiotics. Clinical Microbiology and 
Infection,21(8), 786e1-786e8. doi: 10.1016/j.cmij.2015.04.005 
Vardakas, K. Z., Konstantelias, A. A., Loizidis, G., Rafailidis, P. I., & Falagas, M. E. 
(2012). Risk factors for development of Clostridium difficile infection due to 
BI/NAP1/027 strain: a meta-analysis. International Journal of Infectious 
Diseases, 16(11), e768-e773. doi: 10.1016/j.ijid.2012.07.010 
Varghese, A., Asha, N. S., Celine, T. M., & Prasanna, D. (2015). Inflammatory markers 
in type II diabetes mellitus. The Pharma Innovation Journal, 4(7), 64-66. 
Retrieved from http://thepharmajournal.com/vol4Issue7/Issue_Sep_2015/4-7-
26.1.pdf 
Varki, A., & Gagneux, P. (2012). Multifarious roles of sialic acids in immunity. Annals 
of the New York Academy of Sciences, 1253(16-36). doi: 10.1111/j.1749-
6632.2012.06517.x 
Varki, A., & Schauer, R. (2009). Sialic acids. In A. Varki, R. D. Cummings, J. D. Esko, 
H. H. Freeze, P. Stanley, C. R. Bertozzi, ... M. E. Etzler (Ed.), Essentials of 
glycobiology (2nd ed., Ch. 14). [NCBI Bookshelf [PubReader]. Retrieved from 
http://www.ncbi.nlm.nih.gov/books/NBK1920/ 
Vimr, E. R., Kalivoda, K. A., Deszo, E. L., & Steenbergen, S. M. (2004). Diversity of 
microbial sialic acid metabolism. Microbiology & Molecular Biology Reviews, 
129 
 
68(1), 132-153. doi: 10.1128/MMBR.68.1.132-153.2004rom 
http://thepharmajournal.com/vol4Issue7/Issue_Sep_2015/4-7-26.1.pdf 
Voth, D. E., & Ballard, J. D. (2005). Clostridium difficile toxins: Mechanism of action 
and role in disease. Clinical Microbiology Reviews, 18(2), 247-263. doi: 
10.1128/CMR.18.2.247-263.2005 
Walden University, Center for Research Quality (n.d.).  Research ethics faqs for doctoral 
students conducting research in their own work settings.  Retrieved from 
http://academicguides.waldenu.edu/researchcenter/orec/guides 
Wang, M., Ahrné, S., Jeppsson, B., & Molin, G. (2005) Comparison of bacterial diversity 
along the human intestinal tract by direct cloning and sequencing of 16S rRNA 
genes. FEMS Microbiology Ecology, 54(2), 219-231. doi: 
10.1016/j.femsec.2005.03.012 
Weaver, F. M., Trick, W. E., Evans, C. T., Lin, M. Y., Adams, W., Pho, M. T., … 
Gerding, D. N. (2017) The impact of recurrent Clostridium difficile infection on 
patients’ prevention behaviors. Infection Control & Hospital Epidemiology, 
38(11). 1351-1357. doi: 10.1017/ice.2017.208 
Weeks, D. L., Daratha, K. B., & Towle, L. A. (2009). Diabetes prevalence and influence 
on resource use in Washington State inpatient rehabilitation facilities, 2001 to 
2007. Archives of Physical and Medical Rehabilitation, 90(11), 1937-1943. doi: 
10.1016/j.apmr.2009.06.008 
Wenisch, J. M., Schmid, D., Kuo, H. W., Simons, E., Allerberger, F., Michl, V., … 
Wenisch, C. (2012). Hospital-acquired Clostridium difficile infection: 
130 
 
Determinants for severe disease. European Journal of Clinical Microbiology and 
Infectious Diseases, 31(8), 1923–1930. doi: 10.1007/s10096-011-1522-5 
Wijarnpreecha, K., Sornprom, S., Thongprayoon, C., Phatharacharukul, P., 
Cheungpasitporn, W., & Nakkala, K. (2016). The risk of Clostridium difficile 
associated diarrhea in nasogastric tube insertion: A systematic review and meta-
analysis. Digestive and Liver Disease, 48(5), 468–72. doi: 
10.1016/j.dld.2016.01.012 




Wu, H., Esteve, E., Tremaroli, V., Khan, M. T., Caesar, R., Mannerås-Holm, L., … 
Bäckhed, F. (2017). Metformin alters the gut microbiome of individuals with 
treatment-naive type 2 diabetes, contributing to the therapeutic effects of the drug. 
Nature Medicine, 23(7), 850–858. doi:10.1038/nm.4345 
Yamada, S., & Palmer, W. (2007). An ecosocial approach to the epidemic of cholera in 
the Marshall Islands. Social Medicine, 2(2), 79-88. Retrieved from 
http://www.social.medicine.info 
Yang, X., Xie, L., Li, Y., & Wei, C. (2009). More than 9,000,000 unique genes in human 
gut bacterial community: Estimating gene numbers inside a human body. PLoS 
ONE, 4(6), e6074. doi: 10.1371/journal.pone.0006074 
Young, B. A., Lin, E., Von Korff, M., Simon, G., Ciechanowski, P., Ludman, E. J., 
131 
 
...Katon, W. J. (2008). Diabetes complications severity index and risk of 
mortality, hospitalization, and healthcare utilization. American Journal of 
Managed Care, 14(1), 15-23. Retrieved from http://www.ajmc.com 
Zarowitz, B.J., Allen, C., O'Shea, T., & Strauss, M. E. (2015). Risk factors, clinical 
characteristics, and treatment differences between residents with and without 
nursing home- and non-nursing home-acquired Clostridium difficile infection. 
Journal of Managed Care & Specialty Pharmacy, 21(7), 585-595. doi: 
10.18553/jmcp.2015.21.7.585 
Zhang Q, Xiao X, Li M, Yu M, Ping F, Zheng J, …Wang, X.  (2017) Vildagliptin 
increases butyrate-producing bacteria in the gut of diabetic rats. PLoS ONE 
12(10): e0184735. doi: 10.1371/journal.pone.0184735 
Zhuo, X., Zhang, P., Barker, L., Albright, A., Thompson, T. J., & Gregg, E. (2014). The 
lifetime cost of diabetes and its implications for diabetes prevention. Diabetes 
Care, 37(9), 2557–64. doi: 10.2337/dc13-2484 
Ziakas, P. D., Joyce, N., Zacharioudakis, I. M., Zervou, F. N., Besdine, R. W., Mor, V., 
& Mylonakis, E. (2016). Prevalence and impact of Clostridium difficile infection 
in elderly residents of long-term care facilities, Medicine,95(31), e41873. doi: 
10.1097/MD.0000000000004187  
Zilberberg, M. D., Reske, K., Olsen, M., Yan, Y., & Dubberke, E. R. (2014). Risk factors 
for recurrent Clostridium difficile infection (CDI) hospitalization among 
hospitalized patients with an initial CDI episode: a retrospective cohort study. 




 1 From “Proximal, distal, and the politics for causation: What’s level got to do 
with it?” by N. Krieger, 2008, American Journal of Public Health, 98, p.224.  Copyright 


















Bessie A. Young, MD 
Veterans Affairs Puget Sound Heath Care System (152E), 
Epidemiologic Research and Information Center, 
Seattle, WA 98108, USA 
youngb@uw.edu 
February 15, 2017 
Bessie Ann Young 
Feb 15 
to me 
Hi Kerry, you don't need my permission to use the DCSI-it is in the public domain. I 
don't have access to any of the codes for it. What we did should be listed in the paper. If 
you still need permission, you definitely have it. best, Bessie ----------------------------------
-----------------------------  
Bessie A. Young, MD, MPH Professor, Division of Nephrology, Dept of Medicine 
Section Head VA Nephrology VA Puget Sound Health Care System 1660 S. Columbian 
Way, RDU 111A Seattle WA, 98108 phone: (206) 277-3586 fax: (206) 764-2563 
 
 
Kerry Flint <kerry.flint@waldenu.edu> 
Feb 15 
 
Kerry Flint <kerry.flint@waldenu.edu> 
Jan 22 
to youngb 
Bessie A. Young, MD 
Veterans Affairs Puget Sound Heath Care System (152E), 
Epidemiologic Research and Information Center, 
136 
 
Seattle, WA 98108, USA 
youngb@u.washington.edu 
January 22, 2017 
Dear Dr. Young 
I am a Ph.D. student in the Public Health Program at Walden University, currently 
working on my dissertation. I read your article “Diabetes Complications Severity Index 
and Risk of Mortality, Hospitalization, and Healthcare Utilization” published in the 
American Journal of Managed Care in 2008. The instrument you used to measure 
diabetes severity looks appropriate to measure the disease for my dissertation research. 
Therefore, I would like to request permission to utilize the Diabetes Complications and 
Severity Index (DCSI) described in the article. I would appreciate if you can provide a 
written authorization to utilize this instrument and provide guidance on the steps to gain 
this permission. 
Thank you for your time and consideration. 
Kerry Flint 
Ph.D. Student 
School of Public Health 
Walden University 
Email: kerry.flint@waldenu.edu 
 
 
 
 
 
 
 
 
 
 
